

Al ¹₂

**MEDICAL STATUS OF MARSHALLESE ACCIDENTALLY EXPOSED
TO 1954 BRAVO FALLOUT RADIATION:
JANUARY 1985 THROUGH DECEMBER 1987**

**William H. Adams, M.D., Peter M. Heotis,
and William A. Scott**



MEDICAL DEPARTMENT

**BROOKHAVEN NATIONAL LABORATORY
ASSOCIATED UNIVERSITIES, INC.**

**UNDER CONTRACT NO. DE-AC02-76CH00016 WITH THE
UNITED STATES DEPARTMENT OF ENERGY**

5004095

ERRATA AND CLARIFICATIONS

PG. 1: The third sentence under EXPOSURE GROUPS should begin "In December 1984,...."

PG. 2: The first sentence of the legend of Fig. 1 should read "Percent survivors of the different exposure groups since 1954."

PG. 10: In Table 2 the fourth identification number should read "2197".

PG. 11: In Fig. 3 the name SIFO can be considered the equivalent of Ailingnae, for Sifo Island is part of the Ailingnae atoll.

BNL-52192
UC-408
(Biological Science
DOE/OSTI-4500 — Interim 3)

**MEDICAL STATUS OF MARSHALLESE ACCIDENTALLY EXPOSED
TO 1954 BRAVO FALLOUT RADIATION:
JANUARY 1985 THROUGH DECEMBER 1987**

**William H. Adams, M.D., Peter M. Heotis,
and William A. Scott**

MEDICAL DEPARTMENT

**BROOKHAVEN NATIONAL LABORATORY
UPTON, LONG ISLAND, NEW YORK 11973**

5004097

DISCLAIMER

This report was prepared as an account of work sponsored by an agency of the United States Government. Neither the United States Government nor any agency thereof, nor any of their employees, nor any of their contractors, subcontractors, or their employees, makes any warranty, express or implied, or assumes any legal liability or responsibility for the accuracy, completeness, or usefulness of any information, apparatus, product, or process disclosed, or represents that its use would not infringe privately owned rights. Reference herein to any specific commercial product, process, or service by trade name, trademark, manufacturer, or otherwise, does not necessarily constitute or imply its endorsement, recommendation, or favoring by the United States Government or any agency, contractor or subcontractor thereof. The views and opinions of authors expressed herein do not necessarily state or reflect those of the United States Government or any agency, contractor or subcontractor thereof.

Printed in the United States of America
Available from
National Technical Information Service
U.S. Department of Commerce
5285 Port Royal Road
Springfield, VA 22161

NTIS price codes:
Printed Copy: A04; Microfiche Copy: A01

5004098

DEDICATION

This report is dedicated to the captain and crew of the M.V. Liktanur. For ten years the Liktanurs II and III have served as home and workplace for much of each medical mission to the Marshall Islands. Throughout this time it has been the good fortune of the medical program to have the excellent support of the ship's crew. More importantly, that good fortune was extended to the population served by the medical team: the emergency rigging of oxygen tanks to treat hypoxic patients, lighting of a small airstrip at night to facilitate an emergency air evacuation, radio liaison, transport of patients between the atolls and to and from shore, and the emergency repair of medical equipment are just some of the nonnautical activities that benefited the medical missions. Now, a new support vessel for work in the Marshall Islands has come under contract to the Department of Energy. Therefore, on the departure of the Liktanur, we would like to acknowledge our debt to Capt. Keith Coberly; Monroe Wightman, engineer; Jim Whitney and Jan Kocian, first mates; Cisco Peru, cook; Les Nunes, boatswain; Tony Ned and Mathan Almen, seamen; and other crew members who, for shorter periods, also contributed to the effectiveness of the missions. We thank them for a job well done.

IN MEMORIAM

Two former members of the Brookhaven medical team who participated in several surveys died during the past year. Colonel Austin Lowrey, Jr., died at the age of eighty-six. He was a well-known ophthalmologist with a long career in the army. He was a most kind and generous person and contributed a great deal to the evaluation of possible radiation effects on eyes. Dr. Leo Meyer, who died at age eighty-two, was a well-known hematologist and was Director of the Sickle Cell Anemia Program of the Veterans' Administration. He made outstanding contributions to the program in evaluating hematological radiation effects. Leo will be remembered for his joviality, for always having a joke ready to cheer us. Both of these men were well liked by medical teams and the Marshallese people, and we shall truly miss them.

Robert A. Conard, M.D.
January 23, 1989

CONTENTS

	Page
Introduction	1
Exposure Groups	1
The Marshall Islands Medical Program	1
Policies	1
Procedures	3
Medical Findings	5
Overall Survival	5
Causes of Recent Mortality	5
Rongelap	5
Utirik	5
Comparison population	6
Laboratory Findings	7
Neoplasms	7
Thyroid nodules	7
Nonthyroidal tumors	11
Autoimmune Thyroid Injury	13
Noncancerous Thyroid Morbidity in Exposed Marshallese	14
Review of Cancers in the Comparison Population	17
References	21
Appendices	23

INTRODUCTION

This report updates, through 1987, the medical findings on a population of Marshallese accidentally exposed to radioactive fallout in 1954. The Marshall Islands Medical Program of the Medical Department, Brookhaven National Laboratory, issues these summaries for distribution to institutions and individuals worldwide who are concerned about the adverse medical consequences of radiation exposure in general or, in particular, the plight of the radiation-exposed Marshallese.

The exposed Marshallese population originally comprised 64 persons on Rongelap Atoll who received an estimated 190 rads of whole-body external gamma radiation, 18 on Ailingnae Atoll who received 110 rads, and 159 on Utirik Atoll who received 11 rads. In addition, there were 3 fetuses on Rongelap, 1 on Ailingnae, and 8 on Utirik, each of which received equivalent whole-body doses. Because of radioiodines in the fallout, the thyroid gland received an additional exposure that was much greater than the whole-body dose, although its magnitude was, in part, a function of age at the time of exposure (Lessard et al., 1985).

The content of this report is restricted to the more recent medical findings, some aspects of which bear on late effects of radiation exposure. Those features of the Marshall Islands Medical Program by which medical diagnosis and treatment are provided are discussed. For detailed information on the nature of the 1954 fallout and the acute effects suffered by the population, the reader is referred to several earlier publications (Bond, et al., 1955; Cronkite et al., 1955; Cronkite et al., 1956; Conard et al., 1957). Other reports provide reviews of delayed effects of the exposure (Conard et al., 1980; Conard, 1984; Robbins and Adams, 1989).

EXPOSURE GROUPS

The medical program examines and treats about 800 persons annually. However, the populations on which this report is based include only the exposed persons and a selected group of unexposed individuals. In December 1987, the number of exposed persons was: Rongelap - 50, Ailingnae - 12, and Utirik - 112. For most purposes in this report the Rongelap and

Ailingnae groups are combined and referred to as the Rongelap group, for those persons exposed on Ailingnae atoll were visiting from nearby Rongelap at the time of the fallout. Also examined was the Comparison group that dates from 1957 when 86 unexposed people from Rongelap were selected so that the Comparison group approximated, in age and sex distribution, the exposed Rongelap group (Conard et al., 1958). Sixty persons remain in this group, against which the overall survival of the exposed population is compared (Figure 1). However, a larger unexposed group is also followed. Currently numbering 135, the age and sex distributions of its members were statistically similar to those of the Rongelap and Utirik groups in 1982 (Adams et al., 1983). Included among the 135 are most of the remaining 60 individuals selected in 1957. It is this expanded unexposed population that is used for statistical comparisons of year-to-year medical events; this provides the baseline prevalences from which any unexpected consequences of the radiation exposure can be identified.




Fig. 1: Percent survivors of the different exposure groups since 1964. The number of persons in each group are given in the parentheses.

THE MARSHALL ISLANDS MEDICAL PROGRAM

Policies:

The Marshall Islands Medical Program provides medical care twice yearly to the exposed population by visiting the islands where most now reside, namely Rongelap (and, temporarily, Mejato), Utirik, Ebeye, and Majuro. In addition, the medical team provides health care to a con-

siderable number of unexposed persons. All the inhabitants of Rongelap, Mejato, and Utrik are eligible for medical attention at the time of the team visits to those islands. Team physicians need not be aware of the status of radiation exposure of the individual patient because health care delivery is the same for everyone. The only difference allotted to the exposed population is a U.S. Department of Energy-sponsored referral system to the Marshallese health care system or to tertiary care facilities in the United States for diseases that can reasonably be considered to be radiation-related or for diagnosis of such diseases. Unexposed persons are directed into the referral channels of the Health Services of the Republic of the Marshall Islands whereby referrals are assigned on the basis of priorities set by a medical committee in Majuro.

Any exposed person who has, or who might have, a malignant neoplasm, is referred to secondary or tertiary medical facilities for a definitive evaluation and for therapy if a lesion is found. The usual hospitals to which patients are referred are in Honolulu and Cleveland, the latter because of the presence there of a preeminent thyroid surgeon who has long been involved with the exposed and Comparison groups of Marshallese.

The medical program also dispenses primary medical care and preventive medical services, such as immunizations, during visits to the exposed population. In bringing modern facilities for diagnosis and treatment of disease to the exposed Marshallese, the physicians of the medical program come into contact with children and other family members of the exposed, as well as other inhabitants of the islands. It has been the policy of the Department of Energy to support the medical program in its efforts to provide primary medical care to these individuals on the basis of humanitarian need and as resources permit.

The medical direction of the Marshall Islands Medical Program and the organization of the medical missions to the Marshall Islands are centered at Brookhaven National Laboratory. The staff of the program includes a physician-director, an administrator, and a technical specialist at the Laboratory, and a Marshallese laboratory technician on Ebeye. At the time of the missions a variety of physicians are chosen for the medical team. They are skilled volun-

teers, primarily faculty from medical schools, often with past experience with the program. Logistical support is provided by the Department of Energy, capably facilitated by Holmes and Narver, Inc., Honolulu, HI. The Marshall Islands government, as requested, temporarily assigns nurses, translators, and other health care workers to each mission.

Although there are two medical missions each year, in the interim the exposed population has access to the Marshallese health care system. To expedite exchange of medical information, copies of all examination and laboratory data from the Marshall Islands Medical Program are forwarded to the Marshall Islands Health Service hospitals on Ebeye and Majuro and to the special programs set up for persons from the radiation-affected atolls, currently the 177 Health Care Plan with administrative offices at the Majuro hospital. In addition, copies of the examinations and laboratory data are given to the examinees.

A computer program with data base was developed for portable (lap-top) computers. Computerization of the clinical data permits rapid access while in the field to all findings obtained during the preceding five years of examinations and to selected data collected over more than thirty years. It is hoped that in the near future the development of compatible programs by the Marshallese 177 Health Care Plan will permit sharing of up-to-date problem lists and other medical record items that are important to effective continuity of care.

The Marshall Islands Medical Program, as a satellite clinic of the Clinical Research Center, Brookhaven National Laboratory, is accredited by the Joint Commission on Accreditation of Healthcare Organizations, a nationwide organization that sets standards of performance for institutions dispensing medical care and monitors compliance with those standards. By voluntary participation in the accreditation process, the Marshall Islands Medical Program receives a valuable and impartial external review of its policies and procedures, as well as an assessment of the adequacy of the services it provides. Laboratory and radiological services, medical records, patient satisfaction, pharmaceutical services, and clinical competence of physicians are among the many items reviewed by the Joint Commission.

Much medical data unrelated to radiation exposure is acquired during each medical mission. Some of this information, from exposed and unexposed individuals, is relevant to health care throughout the Marshall Islands. Consequently, public health reports, based on medical team observations unrelated to radiation, have been submitted periodically to the Health Services of the Republic of the Marshall Islands. The topics during this reporting period have included the following:

- 1) Serum lipids in Marshallese
- 2) Pediatric growth and development (an analysis prompted by observations of medical team physicians that Rongelap children, following their transfer to Mejato, were not maintaining their positions on charted growth curves)
- 3) Pediatric audiometry
- 4) Dental conditions on Rongelap and Utirik
- 5) Chlamydia infections in Marshallese women
- 6) Large optic disks (a relatively frequent finding by medical team ophthalmologists)

Some significant observations in these and earlier public health reports were published in medical journals. Moderately elevated serum uric acid levels were noted in many Marshallese and the frequency of this finding and that of gout were analyzed (Adams et al., 1984). Toxoplasmosis was identified as a serious health hazard in the Marshall Islands, with an estimated 200 persons being visually impaired and an incidence of chorioretinitis of 273 cases/year/100,000 seropositive persons (Adams et al., 1987). Hepatitis B, the subject of a serological survey described in a previous Brookhaven National Laboratory report (Adams et al., 1985), constituted another serious public health problem (Adams et al., 1986). The prevalence of anemia in children was described, and normal ranges for hemoglobin level and erythrocyte mean corpuscular volume for Marshallese children were derived (Dungy et al., 1987). The latter were found to be identical to those of children in the United States. Because of the devastating effects of diabetes mellitus among the Marshallese, an effort was made to determine if a dietary deficiency of chromium, a trace element that is relevant to glucose tolerance, contributed to the problem. The analytic proce-

dures used was too insensitive to quantitate blood levels of chromium, but during the analysis it was found that bromine levels were higher than those reported for any other population (Wielopolski et al., 1986). The reason for this is unknown; further, the levels of bromine that were detected fall far short of its known toxic levels. The observation by team ophthalmologists of large optic disks in many persons prompted another report to the Marshallese Health Services because the associated increase in disk cupping could be misconstrued by physicians as representing glaucoma. The high prevalence of the condition indicates Marshallese are unique among all populations in whom such measurements have been obtained (Maisel et al., 1989).

Procedures:

The exposed population, which now numbers 163, must be considered at increased risk for malignant disease as a late complication of radiation injury. Therefore, the medical program has in place a cancer-oriented annual health evaluation. The examination follows the guidelines of the American Cancer Society and includes a medical history, complete physical examination, advice on decreasing risk factors for cancer, advice on self-detection of lesions, annual pelvic examinations and Papanicolaou smears, stool testing for blood, blood count, and urinalysis. Several new diagnostic procedures were incorporated into the medical missions in the past three years. Because of the development of x-ray films and cassettes that significantly decrease radiation exposure, annual mammography is offered to all exposed women and to all unexposed women forty years of age or older. For persons over the age of fifty years, flexible sigmoidoscopy is offered every three years or whenever clinically indicated. An ultrasound machine has been acquired that greatly increases the diagnostic capabilities of the medical team, especially in managing acute problems seen at the time of team visits. For thyroid diagnosis, needle biopsy of selected thyroid nodules has been instituted in an effort to avoid surgery and the subsequent loss of normal thyroid tissue in patients with benign nodular lesions. Because of earlier medical program observations it is known that the exposed are at greater risk for certain endocrine problems and for this reason they receive annual thyroid-

function blood tests and thyroid examinations by a specialist in endocrinology or thyroid surgery. Other tests are performed on a regular basis in an attempt at early detection of malignant nonthyroidal lesions. There is also ongoing monitoring for clinical evidence of immune competence. For exposed persons may be at increased risk for unusual manifestations of infectious diseases.

Medical examinations and services performed during this three-year reporting period were conducted primarily aboard the Liktanur II and the Liktanur III, vessels chartered from U.S. Oceanography. Exceptions, as in the past, included the use of Brookhaven National Laboratory facilities on Ebeye and, when necessary, Marshallese medical dispensaries on Rongelap, Utirik, and Mejato. Laboratory support during the medical missions is provided by several technicians. Routine blood counts are performed on a J.T. Baker 5000 electronic particle counter and sizer. Leukocyte differentials and phase contrast platelet counts are part of each hemogram. A variety of nonhematological testing services is provided, including bacteriology, stool examination, and urine testing. In the past a battery of manual clinical chemistry tests was carried out using commercial spectrophotometric kits. Recently, however, Eastman-Kodak's DT-60 and DTSC analyzers were added to increase the variety of chemistry tests available in the field and to improve the turn-around time for results; this has significantly improved laboratory operation. Fortunately, there have been few problems associated with transport, operation, and handling of the new equipment on board ship, even during bad weather. A Beckman Electrolyte 2 analyzer is used to measure sodium and potassium in serum and urine. Roentgenographic services are performed with a Bennett standard x-ray unit and mammography unit, both of which are contained in a separate module on the deck of the ship. Serum is usually collected from most examinees and frozen for subsequent testing. Referral laboratories have included Bio-Science Laboratories and Accupath in Honolulu for special chemistries and serologies; Pathologists' Laboratories, Inc., Honolulu, for Papanicolaou smears and other cytology; Brookhaven National Laboratory's clinical laboratory for general chemistry and alpha fetoprotein analysis; Hazelton Biotech-

nologies Co., Vienna, VA. for hormone assays; Michael Reese Hospital and Medical Center (Dr. A. B. Schneider, Department of Endocrinology and Metabolism), Chicago, for thyroglobulin analysis; Medical Microbiology Division, University of California, Irvine, for chlamydia culture and serology; and the Eugene L. Saenger Radioisotope Laboratory, University of Cincinnati, for antimicrobial and antithyroglobulin antibody testing (Dr. Harry Maxon).

The Marshall Islands Medical Program is deeply indebted to the many outstanding physicians who, despite the inevitable personal inconvenience, participated in the medical team visits of 1985-1987. It is fair to say that they are the heart of the program. Drawn from excellent medical centers throughout the United States and from private practices, these physicians provide the program with a wide range of up-to-date clinical experience and perspective that contribute to better patient care. The physicians involved in the 1985-1987 missions are listed in Appendix A, and represent the following medical specialties:

- Internal Medicine
- Pediatrics
- Infectious Disease
- Cardiology
- Obstetrics/Gynecology
- Ophthalmology
- Endocrinology
- Surgery
- Gastroenterology
- Family Practice
- Geriatrics
- Allergy/Immunology
- Dermatology
- Neurology
- Pediatric Dentistry

The participation of many excellent medical specialists undoubtedly has been a major factor in the acceptance of the Marshall Islands Medical Program by the population it serves. The percent of persons in the exposed and Comparison groups who appear for the voluntary examinations remains high. For the current reporting period the annual acceptance rates were:

	1985	1986	1987
Rongelap	82%	93%	95%
Utirik	92%	92%	90%
Comparison	76%	66%	72%

The percent of the eligible population examined on at least one occasion during the three year period was:

Rongelap	97%.
Utirik	100%.
Comparison	94%.

These figures do not include several persons residing outside the Marshall Islands. Most exposed persons in this category have medical examinations arranged through a local physician by the Department of Energy or the Marshall Islands Medical Program. The acceptance rate for mammography among eligible women was 100%. For sigmoidoscopy, about 50% of age-eligible persons elect to undergo this procedure on a regular basis.

MEDICAL FINDINGS

Overall Survival:

After thirty-three years there continues to be no significant difference in the survival curves of the high-exposure Rongelap group, the low-exposure Utirik group, and the unexposed Rongelap population followed for the purpose of comparison (Fig. 1). Estimates of the survival distribution by the actuarial life table method were analyzed by Mantel-Cox and Breslow statistics for testing the equality of the survival curves. The "p" values were 0.68 by both techniques. In the Brookhaven National Laboratory report covering January 1983 through December 1984, it was noted that Okajima et al. (1985) suggested that medical programs providing health screening might lead to an underestimation of the effect of radiation on mortality. In particular, it was postulated that this could explain the lower age-specific death rates from all causes among Nagasaki A-bomb survivors, compared to a control population. The effect of medical examinations on the survival of the exposed Marshallese is unknown. On the one hand about 15 percent of the Comparison group selected in 1957 is no longer seen because those individuals have voluntarily foregone examination. In addition, BNL referrals for the Comparison group are channeled into the Marshallese Health Services system, whereas selected medical problems in the exposed groups can be referred directly to tertiary care facilities in the United States. On the other hand, the exposed populations of Rongelap and Utirik have received

equivalent medical attention from the BNL program since 1972, and yet, despite the far higher radiation dose received by the Rongelap group, the survival curves are similar.

Another factor that contributes to the difficulty in interpreting differences in the group survivals in Fig. 1 is that the population used to construct the "Rongelap unexposed" curve was selected in 1957, and it is in that year that their survival is graphed as one-hundred percent; i.e., data from three years of observation, during which some deaths occurred, had already been acquired from the two exposed populations.

Causes of Recent Mortality:

The number of deaths occurring in the last three years are as follows: Rongelap exposed - 2; Utirik exposed - 9; Comparison group - 10. The specific clinical situations are described below.

Rongelap

Subject No. 1. The causes of death listed on the death certificate of this 81-year-old woman in June 1985 were "Inanition" and "Senility." When seen in March 1985, she had a normal blood pressure and cardiac examination revealed "premature beats." In 1984 she was noted to have cataracts, atrial fibrillation, and complaints of urinary incontinence, some cough, constipation, and joint pains. Her hemoglobin was 12.7 g/dl, the mean corpuscular volume was 92 fl, and the white blood cell count was 6,600 per ul with a normal differential.

Subject No. 11. This 81-year-old man died in 1987 of unknown cause. Diagnoses made during the preceding four years included severe osteoarthritis, chronic obstructive pulmonary disease with bullous emphysema, macrocytic anemia that was being treated with vitamin B12 injections, cataracts, and "organic brain syndrome." He had declined a medical examination when visited at his home in September 1986, but did not appear acutely ill at that time.

Utirik

Subject No. 2123. This 47-year-old man died in December 1986 from biopsy-proven hepatocellular carcinoma. His alpha fetoprotein level was elevated and the serum contained hepatitis B surface antigen but no delta antibody. No evidence of tumor was found at his March 1986 examination. Symptoms related to the tumor developed in June of that year.

Subject No. 2125. This patient died in 1987 from carcinoma of the lung with brain metastases at age 70. He had been referred to a Honolulu hospital for evaluation of guaiac-positive stools in October 1986. A chest x-ray was negative at the time of referral. No serious problems were detected during his Honolulu examination, but respiratory symptoms from the tumor developed in January 1987. He had been a cigarette smoker, and was felt to have severe chronic obstructive pulmonary disease with recurrent bronchitis.

Subject No. 2128. This 39-year-old woman had diabetes mellitus complicated by chronic renal failure, severe diabetic retinopathy and neuropathy, and anemia (hemoglobin 9.4 g/dl in October, 1984). She died in a Honolulu hospital after emergency air evacuation from Utirik. Diagnoses made at the hospital included hypoglycemic and hypoxemic brain damage, diabetes mellitus treated with insulin, anemia secondary to renal failure, and sepsis.

Subject No. 2164. "Postpartum hemorrhage" and "uterine inertia" were listed on the death certificate of this 42-year-old woman in February 1985. Previous problems included obesity and possible gout. A blood count in March 1984 was normal.

Subject No. 2189. This 59-year-old woman died in 1987 from chronic renal failure due to diabetes mellitus. Her serum creatinine in March 1986 was 10.9 mg/dl and the hemoglobin level was 7.7 g/dl.

Subject No. 2200. "Inanition" and "senility" were the death certificate diagnoses for this 72-year-old woman who died in December 1985. A thyroid nodule had been noted at least since 1977 but the patient "appeared to be a poor surgical risk." Her hemoglobin level was 11.6 g/dl and the white blood cell count was 6,200 per ul. A left breast mass had been noted since 1966, but the patient had declined biopsy and surgery. She said the mass had been present since youth.

Subject No. 2212. This 66-year-old woman died in 1987 from chronic renal failure due to diabetes mellitus. She was evaluated at Kwajalein hospital in 1985 and noted to have renal failure, hypertension, and anemia. When evaluated by physicians of the 4-Atoll Healthcare

Program she was not felt to be a candidate for dialysis, and her family agreed to supportive management.

Subject No. 2218. The death certificate diagnosis on this 34-year-old woman in September 1985 was "congestive heart failure." When examined in March 1985, the only significant abnormality had been a urinary tract infection for which she was given an antibiotic, although asthma had been noted in the past. The patient was late in pregnancy at the time of her demise and was, on the basis of history obtained from the 4-Atoll program physicians, probably eclamptic.

Subject No. 2249. This woman died at age 57 in February 1986 from complications directly arising from local extension of a "malignant meningioma." A description of this patient and the tumor was presented in a previous BNL report (Adams et al., 1983) following the original diagnosis in 1982.

Comparison group

Subject No. 814. The death certificate diagnosis in June 1985 for this 33-year-old man was pneumococcal meningitis confirmed by culture. He worked on Kwajalein and died in Kwajalein hospital after being transferred from Ebeye hospital. His most recent BNL medical examination had been in April 1983, when problems of smoking and heavy alcohol consumption were noted. His blood count was normal at that time.

Subject No. 821. This 38-year-old woman died in 1986 from complication of childbirth, her death certificate diagnosis being "postpartum hemorrhage." When seen in April 1986 she was 22 weeks into her thirteenth pregnancy. No significant abnormalities were noted at that time.

Subject No. 842. The death certificate diagnosis on this 61-year-old man in March 1986 was "liver failure due to hepatoma." The only active problem noted in his last BNL medical examination in March 1985 was chronic low back pain. A routine sigmoidoscopic examination was normal except for the presence of hemorrhoids. Hepatitis B surface antigen was not detected in his serum, but antibody to the surface antigen was present.

Subject No. 846. This 63-year-old woman underwent a bone marrow aspiration in March

1986 for evaluation of anemia and leukopenia. The diagnosis of refractory anemia with excess blasts was made and subsequently confirmed in Honolulu at the Straub Clinic ("myelodysplastic syndrome with an evolving acute nonlymphocytic leukemia"). She died in 1986.

Subject No. 928. The cause of death in 1987 of this 73-year-old woman is unknown. When last seen by the BNL medical team in Majuro in March 1986, no serious medical illnesses were noted. She had been moderately anemic for several years (hemoglobin level between 10.5 and 11.5 g/dl), and a flexible sigmoidoscopic examination in 1985 was normal. No gastrointestinal blood loss was documented in recent years.

Subject No. 950. This 40-year-old woman died in Kwajalein hospital in August 1985. The death certificate diagnoses were essential hypertension and intracerebral hemorrhage. She had been known to be hypertensive for 13 years and was followed in the hypertension program of the Trust Territories.

Subject No. 969. The clinical diagnosis in this 69-year-old man was either metastatic tumor to the lung or pulmonary tuberculosis. However, the 1987 death certificate diagnoses were "congestive heart failure" and "pneumonia." Sputum cultures for *M. tuberculosis* were negative and there was no clinical response to antituberculous therapy.

Subject No. 975. When splenomegaly and thrombocytopenia were detected in March 1984, this 65-year-old man was referred for further evaluation. A lymph node biopsy in October 1984 showed "atypical lymphoepithelioid cell proliferation of uncertain etiology," possibly a lymphoma. He died in 1985 and details of the terminal illness could not be obtained.

Subject No. 991. This 78-year-old woman died in January 1986. Death certificate diagnoses included "septicemia, diabetes mellitus, and chronic renal failure from diabetic nephropathy." She had a mid-calf amputation of the right leg some six years earlier and was being followed at the Ebeye hospital. Her most recent BNL medical examination was in 1981.

Subject No. 1050. Colon carcinoma with hepatic metastases is the death certificate diagnosis in March 1985 for this 50-year-old woman.

This diagnosis was made after she was referred to Majuro for evaluation of a possible abdominal mass detected in June of 1984.

Laboratory Findings:

A review of average blood cell counts of the different exposure groups during the three-year reporting period does not reveal any systematic differences among groups. Figure 2 is a continuation graph in which the exposed groups are portrayed in relation to the Comparison group. Table 1 gives the actual mean counts of formed blood elements of the different groups and identifies counts which differed significantly from those of the Comparison group.

Biochemical test results are listed by individual identification number in Appendix B.

Neoplasms:

Thyroid nodules

Surgery for palpable thyroid nodules was performed on five persons in 1985 and one person in 1986. No new lesions were detected in 1987. The specific diagnoses, determined by an expert panel of pathologists, are listed in Table 2, and Table 3 gives a summary of all nodules diagnosed throughout the medical program. The benign thyroid nodules include adenomas, adenomatous nodules, and occult papillary carcinomas. The adenomatous nodules are included in the tabulation even though it is highly debatable that they are true neoplasms. The occult papillary carcinomas are, with rare exceptions, "harmless tumors" (Sampson, 1976). A recently reported autopsy series from the Federal Republic of Germany found occult papillary carcinomas in 6.2% of 1020 thyroid glands. Almost half of the tumors were multicentric and 14% had regional lymph node metastases (Lang et al., 1988). Since there was no predilection for age it was concluded, as in earlier studies, that occult papillary carcinomas have no propensity to cause clinically apparent thyroid disease. However, controversy continues on how the clinical diagnosis of occult papillary carcinoma is to be made (Schneider et al., 1980), and some authorities would accept that diagnosis only if the tumor were an incidental finding at surgery. Since some of the purported occult papillary carcinomas removed from the Marshallese patients presumably were palpable before surgery, there may be differing opinions on their clinical, if not histologic, classification.

5004107




Fig. 2: Annual mean blood cell counts of the different exposure groups (age 5 years or more) expressed as percent of control, beginning two years after exposure. Values for both sexes are grouped for neutrophils and lymphocytes. Detailed annual observations, including blood cell counts, on the Utirik population did not begin until 1973. Leukocyte differentials and platelet counts were not obtained for six and five of the examinations, respectively, but for graphing purposes the 100% line has not been broken at those years.

TABLE 1:

Comparison	Rongelap Exposed	Utirik Exposed	
LEUKOCYTES			
1985	7392 ± 1955 (n=96)	6731 ± 1775 (n=48)	7985 ± 1957* (n=100)
1986	7438 ± 2102 (n=78)	7231 ± 2060 (n=54)	7684 ± 2023 (n=98)
1987	7690 ± 1843 (n=78)	7418 ± 1675 (n=49)	8434 ± 3195 (n=90)
NEUTROPHILS			
1985	3948 ± 1433	3716 ± 1524	4606 ± 3948*
1986	3786 ± 1396	3771 ± 1648	4188 ± 1570
1987	3998 ± 1427	3825 ± 1434	4926 ± 2984*
LYMPHOCYTES			
1985	2739 ± 883	2345 ± 860*	2607 ± 915
1986	2785 ± 1131	2811 ± 981	2691 ± 927
1987	2972 ± 950	2915 ± 863	2749 ± 1054
MONOCYTES			
1985	309 ± 168	229 ± 127*	321 ± 177
1986	294 ± 189	301 ± 169	361 ± 251
1987	323 ± 240	307 ± 203	429 ± 311*
BASOPHILS			
1985	12 ± 35	18 ± 38	12 ± 32
1986	40 ± 57	47 ± 59	60 ± 74
1987	53 ± 70	53 ± 58	63 ± 71
EOSINOPHILS			
1985	261 ± 216	284 ± 207	273 ± 238
1986	365 ± 426	297 ± 310	343 ± 322
1987	310 ± 267	293 ± 326	238 ± 239
PLATELETS, MEN			
1985	261 ± 75 (n=38)	242 ± 57 (n=20)	271 ± 51 (n=45)
1986	252 ± 54 (n=33)	240 ± 43 (n=24)	289 ± 66* (n=43)
1987	266 ± 76 (n=35)	240 ± 54 (n=20)	266 ± 55 (n=41)
PLATELETS, WOMEN			
1985	271 ± 61 (n=56)	277 ± 66 (n=28)	299 ± 72* (n=55)
1986	276 ± 71 (n=44)	291 ± 84 (n=30)	328 ± 81* (n=55)
1987	273 ± 67 (n=47)	261 ± 51 (n=28)	308 ± 73* (n=49)
HEMOGLOBIN, MEN			
1985	14.5 ± 1.4	14.8 ± 0.8	14.9 ± 1.2
1986	14.9 ± 1.6	14.7 ± 1.0	15.3 ± 1.3
1987	14.4 ± 1.1	14.6 ± 1.1	15.2 ± 1.3*
HEMOGLOBIN, WOMEN			
1985	13.0 ± 1.2	12.9 ± 1.2	12.6 ± 1.2*
1986	13.0 ± 1.6	13.1 ± 1.4	12.8 ± 1.6
1987	13.1 ± 1.3	13.3 ± 0.8	13.0 ± 1.2

*Significantly different, by t-test analysis, from equivalent values of the Comparison group. The only level of significance tested was $p < 0.05$.

TABLE 2: THYROID SURGERIES, 1985-1987

Identification Number & Group	Age at Diagnosis	Sex	Year of Surgery	Consensus Diagnosis*
67 - Rongelap	45	F	1985	Papillary follicular carcinoma plus occult papillary carcinoma
822 - Comparison	41	M	1985	Normal
2172 - Utirik	45	F	1985	Follicular adenoma
2172 - Utirik	34	F	1985	Occult papillary carcinoma
2225 - Utirik	39	F	1985	Adenomatous nodule
2251 - Utirik	37	F	1986	Follicular adenoma plus occult papillary carcinoma

* Majority diagnoses, based on interpretations by: Dr. L.V. Ackerman, Health Sciences Center, SUNY, Stony Brook, NY; Dr. W.A. Meissner, formerly with New England Deaconess Hospital, Boston, MA; Dr. A.L. Vickery, Massachusetts General Hospital, Boston, MA; Dr. L.B. Woolner, Mayo Clinic, Rochester, MN.

TABLE 3: THYROID NODULES DIAGNOSED AT SURGERY THROUGH 1987

	Adenomatous nodules	Adenomas	Papillary cancers	Follicular cancers	Occult cancers
Rongelap (67)*	17	2	5	-	1
Ailingnae (19)*	4	-	-	-	1
Utirik (167)*	11	4	4	1***	5
Comparison (227)**	4	1	2	-	2****

NOT INCLUDED are the following unoperated (and therefore unconfirmed) nodules: Rongelap — 1; Ailingnae — 1; Utirik — 1; Comparison — 5.

INCLUDED are all consensus diagnoses of a panel of consultant pathologists; two different lesions were detected in one person from Rongelap, one from Ailingnae, and two from Utirik.

* Number of persons (including those *in utero*) who were originally exposed.

** This number includes all persons who have been in the Comparison group since 1957 (see page 18). Some have not been seen for many years; others were added as recently as 1976.

*** Equally divided opinion in one case: follicular carcinoma vs. atypical adenoma.

**** Majority opinion in one case: occult papillary carcinoma vs. follicular carcinoma. The same patient had lymphocytic thyroiditis.

The cumulative experience of benign plus malignant nodule development as a function of age at exposure shows clearly the increased susceptibility of the younger population to nodule induction (Fig. 3). Most benign nodules and all the thyroid carcinomas have occurred in females. It was noted (Robbins and Adams, 1989) that the prevalence of thyroid carcinomas compared to benign nodules (15%) was lower than that reported following medical x-ray therapy (about 30%).




Fig. 3: The accrual of cases with thyroid nodules and thyroid cancer in the exposed Rongelap population as a function of age at the time of exposure in 1954. The <10 year group includes exposure *in utero*. Two cases of thyroid atrophy without nodule formation (2 Rongelap boys, <10 years of age) are excluded. (Figure taken from Robbins and Adams, 1989).

It appears that there is an inverse correlation between the radiation dose absorbed by the thyroid and the time after exposure for development of the benign adenomatous nodules (Fig. 4). However, since the thyroid-absorbed radiation dose was determined primarily by age at exposure (children receiving greater doses than

adults), another interpretation of Fig. 4 is that the time for development of adenomatous nodules following radiation exposure varies directly with age at exposure.

Nonthyroidal tumors

During the period 1985 through 1987, deaths attributable to cancer occurred in three exposed persons, all from Utirik. The types of tumors were: lung cancer, hepatoma, and meningioma. During the same period there were three cancer-related deaths in the unexposed population, the tumor types being: colon carcinoma, hepatoma, and myelodysplastic syndrome.

Additional tumor diagnoses resulted from clinical investigation initiated at the time of medical team visits. These included a case of breast carcinoma (detected by mammography) and a case of colon carcinoma, both diagnosed in exposed Utirik women. Both lesions were surgically resected and have a high probability of being cured. In addition, an epithelioma was removed from the skin of an exposed Rongelap woman, the site of the lesion being in the approximate area of a beta burn that developed soon after the 1954 exposure. This type of lesion, also termed basal cell carcinoma, is very common in the United States and is not included in the detailed cancer statistics published by the American Cancer Society (Silverberg and Lubera, 1987). However, its frequency in Marshallese is unknown.

The development of two cases of hepatoma among the population served by the medical team requires comment. Two persons, one each from the Utirik and the Comparison groups, died from this tumor during the period covered by this report. To this number should be added the death of another Utirik man who died in 1984 from complications of cirrhosis (Adams et al., 1985), for he, like one of the hepatoma patients, had hepatitis B surface antigen detected in his serum. Studies have demonstrated an association between hepatitis B surface antigenemia and hepatoma, cirrhosis, and chronic active hepatitis (Beasley et al., 1981). Early BNL observations revealed that infection with hepatitis B virus is nearly universal among Marshallese, as it is among many tropical populations, and that serological evidence of the infection is common in childhood. In view of the

two fatalities that might be causally linked to hepatitis B virus. Infection with this organism must be considered a public health problem of great concern. The Marshall Islands Medical Program annually tests all persons previously shown to be hepatitis B surface antigen-positive for the presence of alpha-fetoprotein, a tumor marker for hepatoma. Should an elevated level be detected the affected subject would be promptly referred for evaluation in the hope that early detection might permit curative resection of a localized lesion (Heyward et al., 1984).

The question arises as to whether the exposed Marshallese are at increased risk for the late complications of hepatitis B. This problem was

discussed previously (Adams et al., 1986), and it was noted that the prevalence of hepatitis B surface antigenemia was 3.3% in the Rongelap group, 18.8% in the Utirik group, and 10.5% in the Comparison group. There is evidence suggesting an association between radiation dose and prevalence of cirrhosis, but not hepatoma, in survivors of the atomic bombings in Japan (Asano et al., 1982). Assuming that two of the three deaths from hepatoma and cirrhosis in Marshallese resulted from chronic hepatitis B infection, the frequency of hepatitis B-related deaths, as percent of hepatitis B surface antigen-positive persons is: exposed Rongelap - 0% (0/2); exposed Utirik - 9.5% (2/21); Comparison group - 0% (0/10).

ADENOMATOUS NODULES AS FUNCTION OF RADIATION DOSE AND TIME




Fig. 4: The time required to develop adenomatous nodules following radiation exposure appears, in this graph, to be dose-related. However, the thyroid-absorbed radiation dose was highly dependent on the age at exposure.

Autoimmune thyroid injury:

Radiation-induced thyroid hypofunction, diagnosed in fourteen exposed Rongelap individuals, was not found to be increased among Japanese A-bomb survivors. This difference reflects the larger dose absorbed by thyroids of the Marshallese, a consequence of ingestion of radioiodines. The question arises as to whether thyroid hypofunction in the exposed Marshallese is a consequence not only of direct radiation injury, but also of immunologic damage. Immunologic studies by the Radiation Effects Research Foundation found that Japanese A-bomb survivors greater than fifteen years of age at exposure had a significant decrease in mixed lymphocyte culture response that was inversely related to radiation dose (Akiyama et al., 1987), and lymphocyte responses to phytohemagglutinin decreased more rapidly with age in persons who received more than 200 rad. However, the immunological responses of aging Japanese A-bomb survivors do not appear to have been affected by radiation exposure (Bloom et al., 1988), nor does there appear to be an increase in diseases associated with autoimmunity in the exposed Japanese population.

Immunologic damage to the thyroid is mediated, in part, by circulating autoantibodies that are apparently cytotoxic. Antimicrosomal antibodies are important in the diagnosis of autoimmune thyroiditis, a disease process commonly progressing to hypothyroidism (Frey, 1987). Antithyroglobulin antibodies are far less specific an indicator of thyroid autoimmune

disease, but are useful as a screening test. Hypothyroidism is often quite subtle and difficult to diagnose, and any marker that might identify a population at risk for subsequent hypothyroidism would be clinically useful. Therefore 231 Marshallese sera collected in March 1987 were tested for the presence of antithyroglobulin and antimicrosomal antibodies in the laboratory of Dr. Harry Maxon. Fifty-five sera were from the Rongelap-exposed, 94 were from Utirik-exposed, and 82 were from the Comparison group. Two persons had data consistent with the diagnosis of autoimmune thyroid disease (Table 4), and both were in the Comparison group. One was a 38-year-old woman who had Grave's disease with hyperthyroidism diagnosed in 1980 that was treated with 131I. Her serum contained both types of antibodies in 1980 as well as in 1987. The other person, a 32-year-old woman, had an antithyroglobulin antibody level of 35 U/l. She has Sheehan's syndrome, present since 1975 following postpartum hemorrhage. In addition, six persons had nondiagnostic but slightly elevated levels of antithyroglobulin antibodies, two from Rongelap and four from Utirik. None have clinical evidence of autoimmune thyroid disease, although three have had thyroid lobectomies for benign nodules. The lack of evidence for an increase in autoimmune thyroid disease among the exposed Marshallese is consistent with the findings of Radiation Effects Research Foundation studies. In a 30-year followup of persons less than 20 years of age at the time of exposure to the atomic bombings in Japan, no difference was detected in the preval-

TABLE 4: ANTITHYROID ANTIBODIES IN THE DIFFERENT RADIATION EXPOSURE GROUPS.

Exposure group (n)	Elevated antithyroglobulin antibodies*	Percent elevated
Rongelap (55)	2	4%
Utirik (94)	4	4%
Comparison (82)	2**	2%

* The levels ranged between 6 and 11 U/l, with normal levels being ≤ 5 U/l.

** One subject had elevated antimicrosomal antibodies (35 U/l) and a history of Grave's disease with hyperthyroidism.

ence of antithyroglobulin antibodies in unexposed versus exposed groups (Morimoto et al., 1987). In addition, no difference in the prevalence of chronic thyroiditis was found in children considered exposed or unexposed to radioactive fallout in Utah and Nevada (Rallison et al., 1974). Notably, in that study the prevalence of elevated titers of antithyroglobulin antibodies in children with "normal" thyroids was 4.8%. Hypothyroidism is common in aging populations, and in the Framingham Heart Study a clearly elevated thyrotropin (TSH) level was found in 4.4% of persons older than 60 years (Sawin et al., 1985a). The prevalence of antimicrosomal antibodies also increases with age: two-thirds of elderly persons with evidence of thyroid hypofunction had significant levels of antimicrosomal antibodies (Sawin et al., 1985b). The Marshallese data suggest that autoimmune thyroid disease is not common in that population, regardless of a history of radiation exposure.

NONCANCEROUS THYROID MORBIDITY IN EXPOSED MARSHALLESE

The late somatic effects of exposure to ionizing radiation have been equated with cancer induction, the ultimate measure of those effects being expressed in mortality. Since cancer mor-

tality from radiation exposure is low when compared to naturally occurring cancer mortality it is not surprising that there is no observed increase in mortality among the radiation-exposed Marshallese. Nevertheless, much attention has been addressed to their cancer risk. On the other hand, limited attention has been given to morbidity from nonmalignant disease, principally of the thyroid, as a late consequence of radiation exposure, and yet these lesions have been of great clinical importance (Table 5).

A. Thyroid surgery:

Twenty-six (30%) of the Rongelap group and eighteen (11%) of the Utirik group have had surgery for thyroid nodules that were ultimately found to be benign. The types of thyroid nodules found in the exposed population since 1963 can be grouped into cancers, adenomas, and adenomatous nodules. Cancers and adenomas are neoplasms. Adenomatous nodules, which, like adenomas, are benign, are not properly categorized as neoplasms. Histologically, they are hyperplastic lesions. In the exposed population both benign nodules and thyroid hypofunction display a similar correlation with radiation dose (Fig. 5), and, in contrast to thyroid cancer, adenomatous nodules have been very common (see Table 3). Adenomatous nodules are rarely of clinical significance, because they do not evolve into carcinoma. Surgery is necessary only to

TABLE 5: LATE THYROID MORBIDITY UNRELATED TO DIAGNOSIS AND TREATMENT OF THYROID CANCER IN 253 RADIATION-EXPOSED MARSHALLESE.

Morbid event	Number of cases
Thyroid surgery for benign lesions	44
Hypothyroidism, radiogenic	15
Hypothyroidism, postsurgical	21
Hypoparathyroidism, postsurgical	2
Recurrent laryngeal nerve palsy	1
Pituitary tumor*	2
Total morbid events	85

* Possible association (Adams et al., 1984).

exclude that diagnosis. Nevertheless, the clinical evaluation required to establish a diagnosis is associated with its own morbidity. Prominent in this morbidity is thyroid surgery itself, a procedure that requires general anesthesia and results in a cosmetic defect and the unavoidable removal of some normal thyroid tissue.

B. Thyroid hypofunction, radiation-induced:

Overt hypothyroidism was diagnosed in two Rongelap boys who were infants at the time of exposure (Sutow et al., 1965). In addition, subclinical hypothyroidism unrelated to thyroid surgery was confirmed in twelve other Rongelap persons (Larsen et al., 1982). In 1987 a Utirik man was diagnosed as biochemically hypothyroid. He was two years of age at the time of exposure, and he is the first exposed person from Utirik to have this diagnosis.

C. Hypothyroidism, postsurgical:

In 1972 to 1974 it was noted that 11 of 20 exposed persons from Rongelap who underwent surgery for removal of thyroid nodules had elevated levels of thyroid-stimulating hormone (TSH). Because this evidence of postsurgical hypofunction was more frequent than expected it was surmised that thyroid insufficiency might be developing in the exposed Rongelap population as a whole, rather than being limited to the two hypothyroid children diagnosed some ten years earlier (Sutow et al., 1965). Such an event was likely to be clinically inapparent because all of that group had been placed on suppressive doses of thyroxin since 1965 to prevent thyroid neoplasia. Therefore, after temporarily discontinuing thyroxin, a survey of thyroid function was undertaken, and twelve persons were found to have biochemical evidence of thyroid insuffi-




Fig. 5: Thyroid-absorbed radiation dose vs. benign thyroid nodules, carcinoma, and hypofunction.

ciency. Retrospective testing of six persons who had thyroid hypofunction after thyroid surgery revealed the hypofunction had been present earlier (Larsen et al., 1982).

The development of thyroid hypofunction in the exposed individuals continues to be a cause for concern. While the routine use of suppressive doses of thyroxin should render this concern moot, it was noted that, based on medical history or results of annual TSH testing, somewhat more than forty percent of exposed persons who are supposed to be taking thyroxin have evidence of irregular or noncompliance with the prescribed medication regimen (Adams et al., 1983). It is desirable to minimize loss of thyroid tissue at surgery insofar as it is deemed clinically safe to do so: in fact, this has been the practice of the thyroid surgery consultant to the Marshall Islands Medical Program for almost twenty years.

Despite efforts to mitigate loss of thyroid tissue, however, there continues to be evidence of an inordinantly high frequency of postsurgical thyroid hypofunction among the exposed population. Table 6 shows data obtained through 1987 illustrating this point. An increase in frequency of postsurgical thyroid hypofunction with increase in the 1954 thyroid radiation dose is apparent, even though all thyroid surgery patients were advised to take thyroxin. However, the data in Table 6 must represent a minimum estimate of the prevalence of postsurgical thyroid hypofunction. In contrast to the study by Larsen et al. (1982), thyroxin was not pur-

posely discontinued before testing. Therefore, except for those relatively few instances in which selected individuals were asked not to take thyroxin for four to six weeks prior to thyroglobulin testing or thyroid scanning, elevated TSH levels were apparent only because of non-compliance. Some persons may have had normal TSH levels after surgery only because they are adhering satisfactorily to the prescribed thyroxin regimen.

It is unlikely that the differences in prevalence of postsurgical thyroid hypofunction among the groups result from different degrees of compliance in taking thyroxin after surgery. Furthermore, it is likely that, on the average, the extent of resection of thyroid tissue was greater in the unexposed persons undergoing thyroid surgery than in exposed individuals because of concern that the latter were more likely to have impaired thyroid reserve. As Table 6 shows, this concern was well-founded. Although present data are without doubt quantitatively inaccurate, they are likely to be qualitatively adequate.

The distinction between these data and those of Larsen et al. (1982) is that, whereas thyroid hypofunction was found by the latter group to antedate thyroid surgery (as documented by retrospective analysis of stored sera collected before institution of thyroxin suppression in the exposed Rongelap group), the present data reveal an inordinantly high frequency of postsurgical thyroid hypofunction in exposed persons with previously normal TSH levels. The importance of this finding is that there appears

TABLE 6: MARSHALLESE WITH PREVIOUSLY NORMAL TSH LEVELS WHO HAVE DEVELOPED ELEVATED LEVELS FOLLOWING THYROID SURGERY.

Exposure group	Adult thyroid dose (rad)*	Number with surgery	Number with hypothyroidism**	Percent
Rongelap***	1200	23	14	61
Utirik	160	25	7	28
Comparison	none	11	1	8

* Average estimated dose for an adult male.

** Biochemical evidence of thyroid hypofunction as indicated by at least two determinations of thyroid stimulating hormone ≥ 7.0 uU/1. Normal values are less than 6.0 uU/1.

*** Routine thyroxin suppression prescribed.

5004116

to be significantly diminished thyroid reserve in many exposed persons, and, although this diminution is not apparent from routine TSH testing, it frequently may be made clinically significant by thyroid surgery. The extent of the problem cannot be accurately assessed with the data at hand because of the variability in compliance with the taking of the prescribed thyroxin suppression, and because no clinical benefit would accrue to the exposed population from discontinuing thyroxin for the purpose of proving the point. Nevertheless, a 61% prevalence of postsurgical thyroid hypofunction is reason for great concern in view of the high frequency of benign thyroid nodules in the exposed population.

D. Postsurgical hypoparathyroidism:

In two thyroid surgery patients transient postsurgical hypocalcemia was observed. However, two other Rongelap women developed chronic hypoparathyroidism requiring replacement therapy since undergoing thyroid surgery. In one the deficiency was diagnosed postoperatively and has not resolved. In the other the diagnosis was first made twenty years following surgery. Both surgeries were performed on Guam during the early years of the medical program. Postsurgical hypoparathyroidism is not an unusual complication of extensive thyroid surgery, occurring in up to 20% of patients. However, in experienced hands the frequency of postsurgical hypoparathyroidism is much lower.

E. Laryngeal nerve injury:

One Rongelap man has a mild but definite impairment in speech resulting from recurrent laryngeal nerve injury, a well-known complication of thyroid surgery. This is not a common complication, occurring in perhaps 1% of patients. As with postsurgical hypoparathyroidism, its frequency depends greatly on the experience of the surgeon and the extent of the surgery.

F. Pituitary tumor formation:

Two women exposed as young children, one from Rongelap and one from Utirik, have developed pituitary tumors. These tumors are usually benign, causing disease, in part, because of their expansion inside a rigid structure. There is no known direct association between radiation exposure and development of pituitary tumor, but there are reasons to suspect that pituitary tumor formation may be a consequence of thyroid injury (Adams et al., 1984).

In summary, hypothyroidism and subclinical thyroid hypofunction, benign thyroid nodule formation, thyroid surgery with its attendant risks and complications, an excessive prevalence of thyroid hypofunction after thyroid surgery, and possibly pituitary tumors can be considered adverse delayed consequences of radiation injury in the exposed Marshallese. The tally comes to 85 morbid events in 253 persons. In contrast, the only evidence for a "stochastic" effect of radiation exposure has been an increase in thyroid cancers in the Rongelap population, none of whom yet have evidence of residual disease. While several nonthyroidal cancers known to be inducible in humans by external ionizing radiation have been documented in the exposed population, similar cancers have occurred in the unexposed Comparison population of Marshallese. Therefore, one may conclude that in the Marshallese experience the delayed expression of nonmalignant morbidity due to irradiation has indeed been great and far exceeds that of malignant disease.

REVIEW OF CANCER IN THE COMPARISON POPULATION

In earlier BNL publications neoplasms of the exposed population were compared to those of an unexposed "Comparison" population with a similar age and sex distribution. However, since the last report, which brought the period of medical coverage up to December 31st, 1984, concerns have been voiced about present-day safety of habitation on Rongelap island. An analysis of the current radiation risk of Rongelap habitation is not a function of the Marshall Islands Medical Program, which is a clinical program devoted to aspects of health care for persons acutely exposed to radioactive fallout in 1954. Nevertheless, medical information collected over many years concerning the unexposed Rongelap people has been requested by different groups who are involved in assessing that risk. To assist them and others who may wish to review the medical experience of the Comparison population, a summary of diagnoses of neoplastic disease is presented here. It is essential to realize that whatever radiation risk exists today on Rongelap is quite distinct from that incurred by 86 Rongelap inhabitants and 167 Utirik inhabitants during the two-day exposure to Bravo fallout in 1954. The reasons for this statement are given below.

The selection of the Comparison group began in 1957 at Majuro when the group was initiated with 86 individuals matched approximately for sex and age with the exposed group of 86 individuals. Members of the Comparison group were examined periodically thereafter at Rongelap or elsewhere along with members of the exposed Rongelap population. During 1958-59, after the return to Rongelap island, the number of persons actively enrolled in the Comparison group was increased to about 150. During the following years up to 1974, another 31 persons were added. In 1974-76, to make up for more persons lost to followup or deceased, another 32 persons were added. No additions to the roster have been made since that time. When all enrollees are tallied, including those who have discontinued their participation in the annual medical examinations, 227 persons have been examined at one time or another as part of the Comparison group. Although some of the group were lost to followup, there were 63 deaths recorded through 1987. Some deaths may have occurred in those lost to followup that were not brought to the attention of the Marshall Islands Medical Program. Furthermore, the death rate in subsequently added subgroups may not be the same as that for persons in 1957. There is no way to determine if there is any bias introduced into mortality statistics as a consequence of these events which were beyond the control of the program. However, two points can be made. First, since it is cancer mortality which is specifically in question, cancer deaths can be expressed in terms of total known deaths, thereby controlling to some extent for uncertainties in the determination of total deaths. Therefore, on the basis of information made available to the Marshall Islands Medical Program, 8 of the 63 known deaths (13%) may have been due to malignant disease. In the United States cancer mortality accounts for 22% of total mortality (Silverberg and Lubera, 1987), and in the exposed Rongelap group it accounts for 19% of total mortality (5 of 26 deaths). Second, cancer deaths can be expressed in person/years of observation, thereby controlling somewhat for persons lost to followup. When this is done the cancer death rate for the 33-year observation period is 171/100,000 (8 possible cancer deaths in 4669 person/years) for the Comparison group overall and 187/100,000 (4 possible cancer deaths in 2136 person/years) for the 86

persons in the original 1957 Comparison group. The similarity of these numbers does not suggest the introduction of bias in death rates in subsequent additions in the Comparison population. For the Rongelap exposed population, which was statistically similar in age and sex distribution to the Comparison group when evaluated in 1982 (Adams et al., 1983), this number is 234/100,000 (5 possible cancer deaths in 2139 person/years). The confirmed or presumptive cancer diagnoses in the Comparison group are given in Table 7, along with cancer deaths in the exposed Rongelap population.

Table 8 contrasts the distribution of possible cancer deaths in the Comparison group according to years of residence on Rongelap with that of the exposed population. One of the eight persons dying of possible cancer in the Comparison group was never known to be present on the island. Furthermore, six of the eight spent only a short time on Rongelap. However, for those six that short time lay between 1958 and 1961, a period when residual radioactivity would have been higher than in subsequent years. One hundred fifty-one persons in the Comparison population were known to be on Rongelap at some time between 1958 and 1961. Of the six that ultimately died of possible cancer, four were among forty-two who were not on Rongelap after 1961, whereas two were among the one hundred-and-nine that were seen on Rongelap at a later date (Table 9). It is a statistical oddity that even the latter two individuals were found on Rongelap only once after 1961.

There are several points that are relevant for those who would apply an epidemiologic analysis to these data:

1. Since the Marshall Islands Medical Program has not maintained a year-round medical presence on the different atolls where examinees may be found, causes of death were obtained in many instances from records and verbal accounts of health aides and family members living on those atolls and from records and death certificates at the Ebeye and Majuro hospitals. Autopsies are rarely performed in the Marshall Islands.

2. Of the eight deaths that clinically may have been cancer-related, confirmation by tissue diagnosis is available in only four. In the exposed Rongelap population only three of the five deaths attributed to cancer were confirmed.

Table 7 presents limited information relevant to the diagnosis of the cancers in the Comparison group, but all 8 cases have been described in greater detail in this or earlier BNL reports.

3. The most frequent lethal cancers in the United States are lung, breast, colon and leukemia, lymphoma.

4. Areas where health care is limited often have increased mortality from noncancerous disease, and an increase in cancer incidence has been viewed as evidence of improved overall health of some populations because it reflects improvements in longevity.

5. Table 7 lists only deaths that might have been related to cancer. There have been two cases of thyroid cancer that have been diagnosed. The thyroid cancers, discussed elsewhere in this report, have not been a cause of death, and at

the present time there is no evidence of residual disease in either of the thyroid cancer patients.

6. In attempting to determine whether there has been an increase in cancer deaths in either the exposed or Comparison population one should note a Radiation Effects Research Foundation report on the Japanese exposed to atomic bombing. From 1950 to 1985, there had been 5936 cancer deaths among 75991 persons in the LSS (Life Span Study) cohort. Three hundred and forty of the cancer deaths (6% of the total cancer deaths) are thought to be attributable to the 1945 radiation exposure (Preston and Pierce, 1988). The small size of the exposed and Comparison Marshallese groups, the smaller number of cancer deaths, and naturally occurring fluctuations in disease incidence will make statistical detection of any excess cancer mortality impossible in these populations.

TABLE 7: POSSIBLE CANCER DEATHS IN THE RONGELAP EXPOSED AND COMPARISON (UNEXPOSED) POPULATION

ID#	Year of Death	Age at Death	Years on Rongelap*	Cancer Type	Confirmation
A. COMPARISON GROUP					
842	1986	61	2	? Hepatoma	Not available
846	1986	63	4	Leukemia	Yes
861	1960	68	2	Cervix	No. Normal pelvic exam in 3/59.
389	1980	55	2	Breast	Yes
975	1985	65	2	? Lymphoma	"Atypical lymphoepithelioid proliferation"
1005	1984	51	2	Lung	Yes (Smoker)
1050	1985	50	20**	? Colon	No
1571	1982	28	0***	Astrocytoma	Yes
B. RONGELAP EXPOSED					
62	1959	60	2	Ovary	Yes
30	1962	60	5	Cervix	No
13	1966	71	9	Uterus	No
54	1972	19	7	Leukemia	Yes
68	1974	64	16	Stomach	Yes

* Years of residence on Rongelap after rehabilitation of Rongelap island in 1957, as recorded in the medical records of the Marshall Island Medical Program or from personal history.

** Added to Comparison group in 1964; did not live on Rongelap between 1957 and 1964

*** Added to Comparison group in 1976; residence prior to 1976 is not recorded.

**TABLE 8: DISTRIBUTION OF POSSIBLE CANCER DEATHS
ACCORDING TO YEARS OF RESIDENCE ON RONGELAP**

Years on Rongelap	Number of Persons	Possible Cancer Deaths
A. COMPARISON GROUP		
0-4	135	7
5-9	40	0
10-14	20	0
15-19	13	0
20-24	10	1
25-28	9	0
Total	227	8 (13% of recorded deaths)
B. RONGELAP EXPOSED		
0-4	8	0
5-9	10	0
10-14	12	1
15-19	13	0
20-24	30	3
25-28	10	1
Total	83	5 (19% of recorded deaths)

**TABLE 9: COMPARISON AND EXPOSED GROUP
— CANCER DEATHS**

Group	No. in Group	Total Deaths	Cancer Deaths	Age at Death
A. Comparison	227	63*	8	28-68
A.1 Resident on Rongelap <i>only</i> during '57-'61	42	12	4	55-68
A.2 Resident in '57-'61 and for some time thereafter	109	32	2	51-63
A.3 Resident <i>only after</i> '57-'61	47	5	1	50
A.4 Never on Rongelap	29	13	1	28
B. Exposed in 1954	86	26**	5	
B.1 Like A.1	8	3	1	60
B.2 Like A.2	73	20	4	19-71
B.3 Like A.3	1	0	0	
B.4 Like A.4	1	0	0	

* One death occurred five months after return to Rongelap.

** Three deaths occurred prior to return to Rongelap in 1957.

REFERENCES

- Adams, W.H., Harper, J.A., Rittmaster, R.S., and Grimson, R.S. 1984. Pituitary tumors following fallout radiation exposure. *J. Amer. Med. Assoc.* **252**:664-6.
- Adams, W.H., Harper, J.A., Rittmaster, R.S., Heotis, P.M., and Scott, W.A. 1983. *Medical Status of Marshallese Accidentally Exposed to 1954 BRAVO Fallout Radiation: January 1980 Through December 1982*. BNL 51761.
- Adams, W.H., Fields, H.A., Engle, J.R., Hadler, S.C. 1986. Serologic markers for hepatitis B among Marshallese accidentally exposed to fallout radiation in 1954. *Radiat. Res.* **108**:74-9.
- Adams, W.H., Harper, J.A., Heotis, P.M., and Jamner, A.H. 1984. Hyperuricemia in the inhabitants of the Marshall Islands. *Arthritis Rheum.* **27**:713-6.
- Adams, W.H., Engle, J.R., Harper, J.A., Heotis, P.M., and Scott, W.A. 1985. *Medical Status of Marshallese Accidentally Exposed to 1954 BRAVO Fallout Radiation: January 1983 through December 1984*. BNL 51958.
- Adams, W.H., Kindermann, W.R., Walls, K.W., Heotis, P.M. 1987. Toxoplasma antibodies and retinochoroiditis in the Marshall Islands and their association with exposure to radioactive fallout. *Am. J. Trop. Med. Hyg.* **36**:315-20.
- Akiyama, M., Zhou, O-L., Kusunoki, Y., Kyoizumi, S., Kohno, N., Akiba, S., and Delongchamp, R.R. 1987. Age- and dose-related alteration of in vitro mixed lymphocyte culture response of blood lymphocytes from A-bomb survivors. Radiation Effects Research Foundation Tech. Rept. TR-19-87.
- Asano, M., Kato, H., Yoshimoto, K., Itakina, S., Hamada, T., and Iijima, S. 1982. Primary liver carcinoma and liver cirrhosis in atomic bomb survivors, Hiroshima and Nagasaki, 1961-1975, with special reference to hepatitis B surface antigen. *J. Natl. Cancer Inst.* **69**:1221-1227.
- Beasley, R.P., Hwang, L.-Y., Lin, C.-C., and Chien, C.-S. 1981. Hepatocellular carcinoma and hepatitis B virus. *Lancet* **1**:1129-32.
- Bloom E.T., Akiyama, M., Korn, E.L., Kusunoki, Y., Makinodan, T. 1988. Immunological responses of aging Japanese A-bomb survivors. *Radiat. Res.* **116**:343-55.
- Bond, V.P., Conrad, R.A., Robertson, J.S. and Weden, E.A., Jr., *Medical Examination of Rongelap People Six Months After Exposure at Fallout*, W.T.-937, Operation Castle Addendum Report 41.A. April 1955.
- Conard, R.A. 1984. Late radiation effects in Marshall Islanders exposed to fallout twenty-eight years ago. In: *Radiation Carcinogenesis, Epidemiology and Biologic Significance*, pp 57-71. Boice, J.D.Jr. and Fraumeni, J.F. (Editors). Raven Press Inc., New York.
- Conard, R.A., Paglia, D.E., Larsen, P.R., et al. 1980. *Review of Medical Findings in a Marshallese Population Twenty-Six Years After Accidental Exposure to Radioactive Fallout*. BNL 51261.
- Conard, R.A., Cannon, B., Huggins, C.E., Richards, J.B., and Lowrey, A. 1957. Medical survey of Marshallese two years after exposure to fallout radiation. *J. Amer. Med. Assoc.* **164**:1192-7.
- Conard, R.A., Meyer, L.M., Rall, J.E., Lowery, A., Bach, S.A., Cannon, B., Carter, E.L., Eicher, M., and Hechter, H. 1958. *March 1957 Medical Survey of Rongelap and Utirik People Three Years After Exposure to Radioactive Fallout*. BNL 501 (T-119).
- Cronkite, E.P., Bond, V.P., Conard, R.A., Shulman, N.R., Farr, R.S., Cohn, S.H., Dunham, C.L., and Browning, L.E. 1955. Response of human beings accidentally exposed to significant fallout radiation. *J. Amer. Med. Assoc.* **159**:430-4.
- Cronkite, E.P., Bond, V.P., and Dunham, C.L. 1956. *Some Effects of Ionizing Radiation on Human Beings*. AEC-TID 5358.
- Dungy, C.I., Morgan, B.C., Heotis, P.M., Branson, H.E., Adams, W.H. 1987. Normal hematologic values and prevalence of anemia in children living on selected Pacific atolls. *Acta Haematol.* **77**:95-100.
- Frey, H. 1987. Circulating autoantibodies in thyroid disease. *Acta Med. Scand.* **222**:289-91.
- Heyward, W.L., Lanier, A.P., Cartter, M.L., McMahon, B.J., and Bender, T.R. In: *Viral Hepatitis and Liver Disease*. Vyas, G.N., Dienstag, J.L., and Hoofnagle, J.H., eds. Orlando, Florida. Grune and Stratton, Inc., p. 663-4. 1984.
- Lang, W., Borrusch, H., and Bauer, L. 1988. Occult carcinomas of the thyroid: Evaluation of 1020 sequential autopsies. *Amer. J. Clin. Pathol.* **90**:72-6.
- Larsen, P.R., Conard, R.A., Knudsen, K., Robbins, J., Wolff, J., Rall, J.E., Nicoloff, J.T., and Dobyns, B.M. 1982. Thyroid hypofunction after exposure to fallout from a hydrogen bomb explosion. *J. Amer. Med. Assoc.* **247**:1571-5.
- Lessard, E., Miltenberger, R., Conard, R., Musolino, S., Naidu, J., Moorthy, A., and Schopfer, C. 1985. *Thyroid-Absorbed Dose for People at Rongelap, Utirik, and Sifo on March 1, 1954*. BNL 51882.
- Maisel, J.M., Pearlstein, C.S., Adams, W.H., and Heotis, P.M. Large optic disks in the Marshallese population. *Am. J. Ophthalmol.* **107**:145-150.

- Morimoto, I., Yoshimoto, Y., Sato, K., Hamilton, H.B., Kawamoto, S., Izumi, M., and Nagasaki, S. 1987. Serum TSH, thyroglobulin, and thyroid disorders in atomic bomb survivors exposed in youth: 30-year follow-up study. *J. Nucl. Med.* **28**:1115-22.
- Okajima, S., Mine, M., and Nakamura, T. 1985. Mortality of registered A-bomb survivors in Nagasaki, Japan, 1970-1984. *Radiat. Res.* **103**:419-31.
- Preston, D.L. and Pierce, D.A. 1988. The effect of changes in dosimetry on cancer mortality risk estimates in the atomic bomb survivors. *Rad. Research* **114**:437-66.
- Rallison, M.L., Dobyns, B.M., Keating, F.R., Rall, J.E., and Tyler, F.H. 1974. Thyroid disease in children: A survey of subjects potentially exposed to fallout radiation. *Amer. J. Med.* **56**:457-63.
- Robbins, J., and Adams, W.H. 1989. Radiation effects in the Marshall Islands. Elsevier Publishing Co., in press.
- Sampson, R.J. Metastatic occult follicular thyroid carcinoma. 1976. *J. Amer. Med. Assoc.* **236**:1693.
- Sawin, C.T., Bigos, S.T., Land, S., and Bacharach, P. 1985a. The aging thyroid: Relationship between elevated serum thyrotropin level and thyroid antibodies in elderly patients. *Amer. J. Med.* **79**:591-5.
- Sawin, C.T., Castelli, W.P., Hershman, J.M., McNamara, P., and Bacharach, P. 1985b. *The aging thyroid: Thyroid deficiency in the Framingham Study.* **145**:1386-8.
- Schneider, A.B., Favus, M.J., and Frohman, L.A. 1980. Nodules in irradiated thyroids. *N. Engl. J. Med.* **302**:1148-9.
- Silverberg, E., and Lubera, J. 1987. Cancer statistics, 1987. *Ca-A Cancer Journal for Clinicians.* **37**:2-19.
- Sutow, W.W., Conard, R.A., and Griffith, K.M. 1965. Growth status of children exposed to fallout radiation on Marshall Islands. *Pediatrics* **36**:721-31.
- Wielopolski, L., Adams, W.H., and Heotis, P.M. 1986. Blood bromine levels in a Pacific atoll population. *Environ. Res.* **41**:91-8.

APPENDIX A
PROFESSIONAL STAFF PARTICIPATING IN THE
1985-87 MARSHALL ISLANDS SURVEYS

NAME	PARTICIPATING SURVEY	SPECIALTY	AFFILIATION
Adams, W.H.	3/85, 9/85, 3/86 9/86, 5/87, 9/87	Internal Medicine (Hematology)	Brookhaven Natl. Lab. Upton, NY 11973
Anderson, J.	5/87	Internal Medicine (Geriatrics)	NY Bellevue Div. of Geriatric Medicine NY, NY 11016
Arelong, T.	3/85, 9/85, 3/87	Nurse	Armer Ishoda Memorial Hosp., Majuro, MI 96960
Barclay, P.	5/87	Internal Medicine (Allergy/Immun.)	Central General Hosp. Plainview, NY 11803 (Director, Emergency Physicians)
Benes, S.	5/87	Ophthalmology	Ohio State University Medical School Columbus, OH 43210
Beydoun, S.	3/86	Obstetrics/Gyn.	Univ. of Miami School of Medicine Miami, FL 33101
Bliss, M.	3/85, 9/87	Internal Medicine (Gastroenterology)	Boston City Hospital Boston, MA 02118
Cheatham, W.	3/86	Internal Medicine (Endocrinology)	Walter Reed Army Medical Center Washington, D.C. 20012
Dec, W.	3/86	Internal Medicine (Cardiology)	Harvard Medical School Mass. Gen. Hospital Boston, MA 02114
Dobyns, B.	3/85	Surgery	Case Western Reserve Univ. Cleveland Gen. Hospital Cleveland, OH 44109
Engle, J.	3/85, 9/85, 3/86	Family Practice	Vet. Adm. Med. Center Martinsburg, WV 25401 (formerly BNL Resident Physician stationed at Kwajalein)
Ferguson, F.	9/85	Pediatric Dentistry	School of Dental Medicine State Univ. of New York at Stony Brook, NY 11791
Giorgio, B.	3/85, 5/87	Gyn. Surgery	Private Practice Pearl City, HI 96782
Giorgio, L.	3/85	Nurse	Pearl City, HI 96782
Greene, G.	9/85	Pediatrics	Univ. of California Irvine Medical Center Orange, CA 92668

NAME	PARTICIPATING SURVEY	SPECIALTY	AFFILIATION
Harper, J.	9/86	Family Practice	Private Practice Portland, ME 04103 (formerly BNL Resident Physician stationed at Kwajalein)
Jacobs, D.	3/86	Nurse	Armer Ishoda Mem. Hospital, Majuro, MI 96960
Jensen, L.P.	3/85	Obstetrics/Gyn.	University of Miami School of Medicine Miami, FL 33101
Kabua, J.	3/85, 9/85, 3/86 9/86, 5/87, 9/86	Nurse	Ebeye Marshall Islands, 96960
Kehne, S.	3/85, 3/86	Internal Medicine (Pediatric Neurology)	Boston City Hospital Boston, MA 02118
Kindermann, R.	3/85	Ophthalmology	Private Practice Cherry Hill, NJ 08003
Lakshmanan, M.	3/86, 5/87	Internal Medicine	Natl. Institutes of Health Bethesda, MD 20892
Landsberger, E.	3/86	Obstetrics/Gyn.	Albert Einstein College of Medicine, Bronx, NY 10461
Langrine, H.	3/85, 9/85, 3/86	Nurse	Armer Ishoda Mem. Hospital, Majuro, MI 96960
MacKay, D.	5/87	Internal Medicine (Infectious Diseases)	Dartmouth-Hitchcock Medical Center Hanover, NH 03756
Maisel, J.	3/85	Ophthalmology	State Univ. of New York at Stony Brook, NY 11791
Maxon, H.	5/87	Internal Medicine (Nuclear Medicine Thyroidology)	University of Cincinnati Medical Center Cincinnati, OH 45267
McClintock, C.	3/85	Internal Medicine (Gastroenterology)	Boston City Hospital Boston, MA 02118
Melkonian, R.	5/87	Obstetrics/Gyn.	Stony Brook Univ. Hospital SUNY at Stony Brook, NY 11791
Mellan, M.	5/87	Nurse	Armer Ishoda Mem. Hosp. Majuro, Mashall Is., 96960
Pacifico, A.	5/87	Internal Medicine (Cardiology)	Baylor College of Medicine Houston, TX 77030
Panebianco, R.	3/85	Internal Medicine	Private Practice Southampton, NY 11968
Rittmaster, R.	3/85	Internal Medicine (Endocrinology)	Natl. Institutes of Health Bethesda, MD 20892 (Formerly BNL Resident Physician stationed at Kwajalein)

NAME	PARTICIPATING SURVEY	SPECIALTY	AFFILIATION
Stewart, D.	9 85	Pediatrics	University of California Irvine Medical Center Orange, CA 92668
Symes, D.	5 87	Ophthalmology	Private Practice Tucson, AZ 85718
Ugolini, V.	5 87	Internal Medicine (Cardiology)	University of Texas Southwestern Medical Ctr. Dallas, TX 75235
Werth, V.	3 86	Internal Medicine (Dermatology)	New York University Dept. of Dermatology NY, NY 10017
Williams, K.	3 86	Internal Medicine	Cornell University Department of Medicine NY, NY 10032

TECHNICAL SPECIALISTS PARTICIPATING IN THE 1985-87 MARSHALL ISLANDS SURVEYS

NAME	PARTICIPATING SURVEY	AFFILIATION
Adams, Diana	3 85	Medical Department Brookhaven National Laboratory Upton, NY 11973
Ankien, Risong	3 85, 5 87	Armer Ishoda Memorial Hospital Majuro, Marshall Islands 96960
Boyd, Lindora	9 85	Medical Department Brookhaven National Laboratory Upton, NY 11973
Bullis, James Jr.	3 86	Medical Department Brookhaven National Laboratory Upton, NY 11973
deBrum, Reynold	3 85, 9 85, 3 86 9 86, 5 87, 9 87	U.S. Department of Energy Majuro, Marshall Islands 96960
Duhaime, Susan	5 87	Stony Brook University Hospital, State University of New York at Stony Brook, NY 11791
Emos, Helmer	3 85, 9 85, 3 86 9 86, 5 87, 9 87	Medical Department Brookhaven National Laboratory Stationed at Ebeye, Marshall Islands
Gideon, Kalman	3 86	Armer Ishoda Memorial Hospital Majuro, Marshall Islands 96960
Heotis, Peter	3 85, 9 85, 3 86 9 86, 5 87, 9 87	Medical Department Brookhaven National Laboratory Upton, NY 11973
Heinrichs, John	5 87	Medical Department Brookhaven National Laboratory Upton, NY 11973
Jacob, Stanley	3 85, 3 86	Ebeye Hospital Ebeye, Marshall Islands 96960
Lehman, William	9/86, 5/87, 9/87	Medical Department Brookhaven National Laboratory Upton, NY 11973
Saul, Joe	3/85, 9/85, 3/86	Armer Ishoda Memorial Hospital Majuro, Marshall Islands 96960
Scott, William	3/85, 9/85, 3/86 5/87, 9/87	Medical Department Brookhaven National Laboratory Upton, NY 11973
Shoniber, Sebio	3 85, 9 85, 5 87	Armer Ishoda Memorial Hospital Majuro, Marshall Islands 96960
Stravino, Michael	3 85, 9 85, 3 86	Medical Department (Retired) Brookhaven National Laboratory Upton, NY 11973
Tommy, Morris	5 87, 9 87	Armer Ishoda Memorial Hospital Majuro, Marshall Islands 96960

APPENDIX B

Individual Marshallese laboratory data collected during the 1985, 1986, and 1987 medical surveys. (Identification numbers 1 to 86 belong to exposed persons of Rongelap and Ailingnae; numbers beginning at 2102 belong to the Utrik exposed; numbers from 805 through 1578 belong to the Comparison group).

Abbreviations:

PID = Brookhaven National Laboratory identification number
SEX = 1 - Male; 2 - Female
AGE = years
WBC = leukocyte count/ μ l
PMN = neutrophil count/ μ l
BAND = band forms/ μ l
LYMPH = lymphocytes/ μ l
MONO = monocytes/ μ l
EOS = eosinophils/ μ l
BASO = basophils/ μ l
PLT = platelet count $\times 10^3$ / μ l
HCT = percent
RBC = erythrocytes $\times 10^3$ / μ l
MCV = mean corpuscular volume in fl
HGB = hemoglobin level in g/dl
TSH = thyroid stimulating hormone level in μ U/l
PRL = serum prolactin in ng/ml
T4 = thyroxine in μ g/dl
TPR = total protein in g/dl
ALB = albumin in g/dl
GLOB = globulin in g/dl
A/G = albumin/globulin ratio
CAL = calcium in mg/dl
FBS = fasting blood sugar in mg/dl
HBA1C = glycosylated hemoglobin A1C in percent

5004128

PID	SEX	AGE	COMPUTER LISTING OF 1985 RAW DATA										TSH	PRI	T4		
			WBC	PMN	BAND	LYMPH	MONO	EOS	BASO	PLT	HCT	RBC				MCV	HGB
2	1	33	7900	4898	188	2133	318	318	79	224	42.9	4.45	96	15.0	16.60	4.5	10.4
4	1	70	9500	5890	95	2680	570	190	95	184	46.1	5.28	88	14.9	6.20	2.2	
5	1	33	8100	2682	0	2989	244	305	0	281	42.7	4.51	96	14.1	5.00	2.3	
7	1	66													5.60	11.9	
9	1	52	8900	3933	2001	828	138	278	0	245	43.6	4.48	98	15.2	3.20		6.2
10	1	66	10800	7245	106	2415	625	210	0	278	45.4	5.39	84	14.8	2.80	3.0	
12	2	48	7800	3498	78	3498	228	304	0	410	40.3	4.27	94	13.2	5.10	2.7	
14	2	58	6100	2858	61	1883	204	308	0	229	34.3	3.49	98	11.7	6.30	2.6	
15	2	39	8900	3918	0	4539	358	89	0	309	42.1	4.48	94	13.8	36.00	21.7	
16	1	71	4800	2484	138	1810	322	48	0	320	43.8	5.88	74	13.9	17.00	6.3	
17	2	35	6400	3778	266	1792	384	128	64	198	48.9	5.04	93	12.9	2.60	18.1	
18	2	63	6700	3078	171	1787	285	399	0	313	39.6	4.31	92	12.7	6.90	15.0	
19	1	37	7300	4528	73	2044	219	438	0	202	45.1	5.98	75	14.3	68.00	12.9	3.9
20	1	38	8200	6858	82	2298	164	0	0	292	51.1	5.78	86	16.4	8.20	4.8	7.9
21	2	34	4300	2823	43	1032	172	430	0	220	41.1	5.04	82	13.7	2.60	17.2	
22	2	47	8100	2745	122	2684	122	427	0	281	46.6	5.85	98	12.8	5.30	13.6	
23	1	38															
24	2	45	7400	3700	0	2812	298	518	74	202	38.7	4.24	91	13.8	2.90	3.1	
27	1	65	7500	3625	225	2925	225	525	78	243	43.2	4.38	99	14.8	3.10	1.3	
34	2	78	7800	4680	390	2418	158	158	0	239	34.3	3.48	98	11.7	10.60	11.1	
36	1	39	8200	3598	188	1984	372	62	0	272	47.3	4.69	101	15.6	5.00	4.3	8.0
37	1	52	4100	2050	41	1478	41	410	82	200	39.3	4.10	98	13.8	5.70		
39	2	48	8200	3348	0	2294	372	188	188	320	40.4	4.27	93	12.4	5.00		
40	1	61	4900	1882	49	2842	98	49	0	208	42.4	4.53	94	13.9	3.90	5.8	
41	1	73	6500	3770	0	2080	130	520	0	188	44.0	4.61	95	13.9	6.00	4.8	
42	2	34	7700	4468	0	2895	308	231	0	231	48.7	5.11	91	15.2	3.10	11.8	14.2
44	1	38	6000	2700	100	2050	100	50	0	280	45.8	5.40	86	14.8	6.20	3.2	9.4
49	2	48	6400	2498	64	3072	320	448	0	244	43.8	4.81	91	13.4	6.00	2.9	4.3
61	2	40	7400	3330	0	3922	148	0	0	388	41.2	4.58	90	13.7	35.00	7.1	
63	2	67	6800	3332	204	2040	0	1168	0	268	39.9	4.24	94	13.1	4.60	3.8	
65	2	33	4800	2498	48	1880	192	338	48	298	33.5	3.73	90	10.8	188.00	38.3	
66	2	61	6800	3488	204	2652	204	272	0	241	38.7	4.20	92	12.7	10.30	3.9	
67	2	45	7900	4187	318	3081	79	168	0	208	41.1	4.29	98	13.3	3.20	6.6	11.0
71	2	68	7000	2800	0	3380	360	490	0	198	38.7	4.19	92	13.0	8.50	5.3	
72	2	39	7800	5018	0	1900	380	304	0	398	39.7	4.39	90	13.0	3.80	22.3	13.8
74	2	47	8900	2780	89	3450	345	207	69	304	47.5	5.30	90	16.1	3.40	6.5	16.8
75	2	43	11400	8208	342	2508	228	114	0	248	41.9	4.50	93	13.2	13.10	6.7	9.9
76	1	42	5000	1800	0	2700	200	260	50	158	43.8	4.41	99	14.8	3.30		6.1
77	1	66	5400	3584	182	1668	54	54	0	334	40.3	4.24	95	13.2	4.00	4.9	
78	2	67	7800	3120	0	4368	78	234	0	320	40.0	4.03	99	13.3	3.60	4.7	
79	1	71	7900	4582	79	2449	395	398	0	148	47.8	5.14	93	15.5	4.60	4.9	
83	1	32	5400	2592	0	2062	324	324	0	265	46.7	4.75	98	16.5	2.80	4.3	8.5
85	1	31	8800	4844	0	3528	344	88	0	345	48.8	5.14	95	14.8			
86	2	31	7000	5040	350	1190	140	280	0	232	31.1	3.38	92	10.8	4.80		
8	2	33	11000	8910	330	1210	0	550	0	218	31.5	3.62	87	10.6	10.70	69.9	
45	2	63	4500	2340	135	1305	225	450	45	298	34.7	3.67	95	12.1	3.10	5.2	
53	2	39	6800	3388	0	2804	188	132	0	380	43.4	4.61	94	14.3	9.80		12.1
70	2	48	3500	2275	0	980	140	108	0	211	36.0	4.24	85	12.3	3.60	5.7	12.4
81	2	41	4200	2804	42	1302	128	128	0	408	38.7	4.31	90	13.0	5.30	10.4	6.2
84	1	30	4800	2084	192	1778	192	578	0	199	50.0	5.28	95	15.0	3.00		
2102	1	42	8400	4538	0	3278	504	0	84	380	48.5	4.92	99	18.8	1.80		
2103	1	75	9700	6402	291	2425	388	194	0	281	43.7	4.48	98	13.8	3.90		
2104	2	55													6.40		
2105	1	77	11500	7360	0	2990	345	230	0	310	41.2	4.58	90	13.1	3.90		
2106	1	38	12800	6798	252	5418	758	378	0	313	49.8	5.79	88	16.9			

5004129

COMPUTER LISTING OF 1985 RAW DATA																	
PID	SEX	AGE	WBC	PMN	BAND	LYMPH	MONO	EOS	BASO	PLT	HCT	RBC	MCV	HGB	TSH	PRI.	T4
2107	2	67	12800	7298	788	3988	384	384	0	202	42.9	4.77	90	13.7	1.30		
2108	1	43	7200	4032	144	2808	0	216	0	333	43.3	4.81	90	15.1	1.30		
2110	1	79	7800	4880	158	2282	312	390	0	244	39.9	3.97	101	12.8	6.40		
2111	2	38	8900	6340	0	2870	448	448	0	381	39.8	4.87	82	13.1	3.80		
2113	2	38	8200	6248	0	2214	410	328	0	348	38.9	4.90	79	13.8	4.00		
2114	1	72	8400	3778	288	2048	188	192	0	521	48.8	5.41	89	13.9	3.90		
2116	1	31	8800								44.7	5.80	86	14.6			
2117	2	88	8800	4780	88	2978	428	288	0	880	37.7	4.04	83	13.8			
2119	2	60	8400	3948	84	3898	420	282	0	238	40.4	4.88	89	13.4	2.80		
2123	1	48	8000	3800	80	2180	120	0	0	204	47.1	4.88	97	15.8	3.20		
2124	1	32	8800	4884	88	3344	818	88	0	384	48.8	5.38	91	18.0	3.20		
2126	1	68	8700	3283	0	3149	134	134	0	280	47.1	4.84	97	15.1	4.10		
2128	2	40	8200	3834	82	2048	372	82	0	280	41.2	4.81	91	13.1	3.10		
2129	2	49	8000	4180	80	2320	860	880	0	421	40.7	5.00	81	13.2	4.10		
2130	2	34	8100	4392	81	1281	244	122	0	204	34.8	3.88	89	11.4	6.00		
2134	2	32	8700	1740	87	6688	348	622	0	308	39.3	3.90	90	12.3	3.40		
2136	1	38	8200	4182	0	2842	328	492	82	238	48.4	4.88	98	14.3	4.30		
2137	1	47	8000	3300	0	2280	120	300	0	238	48.9	5.11	90	14.4	3.80		
2138	2	38	10500	6818	0	2208	210	1470	0	488	40.4	4.81	88	12.8	3.20		
2139	2	87	8800	3380	88	2408	280	390	0	304	37.9	4.01	98	12.2	6.20		
2140	2	78	8400	4098	0	1792	320	0	0	214	40.1	4.17	98	12.8	6.80		
2142	1	37	11200	7188	112	3472	112	338	0	209	61.8	3.20	97	16.4	4.20		
2143	1	34	8400	3328	0	2304	384	384	0	408	41.0	4.77	88	12.8	7.40		
2146	1	64	8100	2928	183	2801	244	244	0	287	41.8	4.30	91	13.7	6.40		
2147	2	37	8300	1802	83	3180	189	108	0	388	41.7	4.89	89	14.7	2.40		
2148	1	78	9800	6228	380	3420	288	190	0	244	42.3	4.48	98	13.7	4.70		
2149	2	40	8800	3018	0	2438	290	88	0	288	38.2	4.33	88	11.4	4.40		
2150	1	44	9300	5880	188	2883	188	488	0	208	49.8	5.84	88	16.2	4.80		
2152	1	49	8800	3080	88	1860	330	220	88	288	43.8	4.89	93	14.7	2.90		
2153	1	34	4900	3479	49	1078	147	147	0	288	48.4	5.81	84	13.2			
2155	1	32	8200	2388	0	3182	372	310	0	284	48.7	5.78	84	16.1	3.80		
2156	1	40	8400	3904	0	2048	320	128	0	272	48.4	4.98	92	14.8	3.00		
2158	2	61	7000	4830	0	1810	420	140	0	279	39.8	4.31	92	13.0	4.10		
2159	2	37	8100	6427	243	2108	324	81	0	394	43.1	4.87	92	13.8	4.70		
2160	2	38	8000	6200	320	1440	480	880	0	298	48.0	4.79	94	14.0	6.00		
2182	2	84	7400	4814	148	2220	298	222	0	399	38.8	4.02	89	11.4	6.30		
2185	1	43	7800	3888	78	3888	312	188	0	229	43.8	4.94	88	14.8	3.40		
2186	1	89	7800	3888	78	2984	488	848	78	288	48.8	4.74	98	13.9	6.80		
2187	1	48	7800	3744	312	3198	488	78	0	211	48.9	5.32	88	16.3	3.20		
2171	2	34	8800	6018	428	2210	170	898	88	280	41.2	4.80	90	13.0	2.80		
2172	2	44	7100	6041	142	1833	142	142	0	338	37.4	4.08	92	12.8	3.30		
2174	1	32	8800	6338	0	1872	440	284	88	288	51.8	5.78	89	18.9	4.40		
2178	1	42	8800	3128	88	3400	204	0	0	233	44.9	4.88	98	14.8	4.80		
2179	1	34	8100	4880	0	2873	408	182	0	223	51.0	6.28	81	16.8	3.00		
2182	2	84	4800	1794	0	2878	138	92	0	372	34.8	3.74	93	11.8	4.80		
2188	1	34	8800	4400	178	2818	880	440	88	181	64.7	5.91	93	16.8	4.30		
2189	2	69	8400	6882	188	788	338	804	84	218	31.7	3.48	92	10.3	3.70		
2193	2	83	8900	4130	298	1478	0	0	0	300	40.1	4.30	93	13.0	4.80		
2198	2	88	8700	3484	87	2747	201	87	0	388	40.0	4.88	82	13.4	4.70		
2198	2	70	8800	2880	88	3188	328	88	0	204	41.8	4.70	88	13.2	27.00		
2197	2	33	8300	3180	83	2487	282	318	83	171	33.1	3.73	89	10.9	4.70		
2200	2	74	8200								38.8	3.78	94	11.8			
2206	1	61	9200	4784	92	3880	480	184	0	291	43.7	4.98	88	13.7	3.90		
2208	1	64	9200	4808	184	3888	278	184	92	240	47.0	5.13	92	14.8	2.40		
2207	1	37	10100	6889	404	3232	303	101	101	309	47.8	5.80	88	14.8	3.30		

5004130

PID	SEX	AGE	COMPUTER LISTING OF 1986 RAW DATA										TSH	PRL	T4		
			WBC	PMN	BAND	LYMPH	MONO	EOS	BASO	PLT	HCT	RBC				MCV	HGB
2208	2	89	8600	6862	788	2018	384	480	0	300	40.2	4.37	92	13.6	4.10		
2209	2	37	8400	6964	0	1848	604	84	0	344	40.1	4.31	93	12.3	3.80		
2210	2	32	6400	3712	64	2240	192	612	0	213	44.8	4.88	90	13.7	3.60		
2212	2	66	7200	3960	216	2620	144	360	0	211	39.3	4.23	92	12.6	9.80		
2213	2	33	6300	3869	83	424	212	212	0	278	36.9	4.19	88	11.6	1.90		
2216	2	68	9400	6462	470	2914	262	262	0	442	43.7	6.09	88	14.1	2.30		
2217	2	63	7400	4440	74	2220	296	370	0	220	39.0	3.92	99	12.8	4.30		
2218	2	31	7600	4200	76	2700	460	76	0	242	39.1	4.30	91	12.7	6.90		
2220	2	67	6700	3866	134	2010	336	336	0	260	39.0	4.16	94	13.0	6.00		
2221	2	64	14900	10430	1192	2662	447	0	149	232	39.6	4.30	92	12.8	6.60		
2224	2	63	8200	6084	666	2060	246	164	0	329	38.0	3.97	96	11.9	3.80		
2226	2	38	8400	3192	262	4704	84	168	0	220	37.8	4.30	87	12.3	6.40		
2228	2	33	6600	3410	110	1870	110	0	0	263	37.9	4.68	81	12.3	141.00		
2227	2	36	6600	3036	196	2674	396	396	0	424	39.9	6.39	74	10.6	3.70		
2228	2	40	14200	8236	666	3660	994	662	0	310	39.4	4.34	91	12.6	3.70		
2229	2	60	7800	6226	166	2184	312	312	0	244	46.2	4.94	94	11.3	3.20		
2230	2	44	8000	6896	0	1936	616	264	0	366	46.3	6.22	87	14.8			
2231	2	33	7700	4312	164	2618	462	164	0	349	42.6	4.69	87	13.7	3.60		
2232	1	34	8200	4610	82	2670	410	326	0	260	62.4	6.47	96	17.1	7.60		
2233	1	33	7000	3670	0	2310	700	420	0	266	49.6	6.31	93	16.6	6.20		
2234	1	46	12600	6376	0	3260	260	626	0	266	64.6	6.03	90	16.3	4.60		
2236	1	39	12800	6784	384	4608	612	612	0	244	44.0	4.77	92	14.6			
2236	1	43	6300	3213	0	2646	378	63	0	267	44.0	6.11	86	14.6	11.30		
2239	2	36	8000	6600	0	1660	240	480	0	366	32.8	3.66	90	11.6	1.00		
2242	1	32	9300	7719	279	930	93	0	0	263	40.2	4.62	89	13.6	2.90		
2244	2	76	7000	3920	210	2730	140	0	0	339	36.9	3.64	93	11.6	3.60		
2246	1	32	8900	6319	178	1691	634	178	0	268	44.8	4.69	96	14.6	4.60		
2247	2	40	8400	4672	336	2268	604	420	0	332	36.1	4.26	86	11.4	2.60		
2248	2	47	9600	7164	490	1176	668	294	98	276	42.8	4.91	81	13.4	2.80		
2260	1	42	8400	6376	84	2436	84	420	0	277	49.3	6.64	89	16.9	2.90		
2261	2	37	8900	4183	0	4626	69	0	0	294	37.6	4.92	77	12.2	4.90		
2264	2	36	8200	3666	248	1674	124	496	0	208	29.6	3.66	84	9.7	9.40		
2266	2	31	8300	3662	166	3164	249	1079	0	264	43.6	4.69	89	13.6	6.00		
2266	2	37	8600	4676	340	3400	66	0	0	391	40.6	4.61	89	13.7	3.20		
2267	1	39	8200	3644	248	1736	310	62	0	262	43.4	6.21	83	14.2	4.90		
2269	2	32	8100	3321	81	4212	243	243	0	262	42.3	4.66	87	14.4	2.60		
2261	1	67	6600	3706	260	2060	196	196	66	204	48.3	6.02	96	16.6	4.70		
2269	1	31	11300	7664	226	2936	226	226	0	226	48.3	6.11	96	16.3	4.00		
2271	1	31	6800	3400	66	2666	272	204	0	361	46.6	6.14	89	16.7	4.80		
2274	1	31	6900	3174	136	3312	69	207	0	338	44.6	6.12	88	14.3	6.00		
2277	2	33	6200	3348	124	2232	372	62	0	222	30.0	4.99	60	6.4	6.30		
806	2	32	6400	2368	0	3326	192	446	64	369	44.7	6.16	87	12.6			
811	2	33	9100	4096	182	3913	162	637	91	268	44.0	4.66	98	13.3			
816	1	37	6100	2806	0	2040	102	163	0	160	43.1	6.02	86	16.9			
816	2	36	7200	3312	144	2692	216	936	0	269	38.6	4.46	86	12.4			
816	1	36	6100	3721	0	2013	244	122	0	411	62.2	6.67	94	16.1			
821	2	36	6900	4140	0	2277	276	207	0	268	36.0	3.96	88	11.2			
822	1	41	8200	4016	164	2962	410	674	82	241	44.6	6.10	86	14.6			
823	1	42	6600	3026	66	1696	220	660	66	240	46.6	4.66	100	16.3			
826	2	43	6300	2961	126	2646	262	262	63	306	40.7	4.67	87	13.1			
826	2	49	6700	3646	266	1197	266	266	0	224	40.9	4.46	92	12.1			
827	1	46	8400	6292	166	2100	336	420	84	326	46.0	4.69	94	16.3			
829	2	46	4300	2193	0	1677	266	172	0	260	41.2	4.37	94	12.2			
830	1	47	6200	2704	0	2026	260	206	0	264	46.6	4.96	94	14.6			
831	1	46	6000	1980	120	3640	120	240	0	262	62.6	6.62	93	16.6			

5004131

COMPUTER LISTING OF 1986 RAW DATA																	
PID	SEX	AGE	WBC	PMN	BAND	LYMPH	MONO	EOS	BASO	PLT	HCT	RBC	MCV	HGB	TSH	PRI.	T4
832	2	48	8800	3318	0	2730	130	328	0	281	38.7	4.82	81	12.2			
833	1	53	4100	1927	0	1848	82	41	0	184	48.3	4.90	88	18.4			
834	1	52	7800	3378	78	3780	300	0	0	299	49.1	6.47	90	18.8			
838	2	52	10800	6818	108	4240	424	106	0	280	42.8	4.48	98	14.8			
838	1	54	8800	4782	178	3344	382	178	0	249	83.3	6.48	98	18.1			
839	2	59	7800	2282	78	4788	848	188	0	321	47.1	4.98	98	14.2			
840	1	56	10900	4878	218	8480	848	109	0	368	48.9	8.82	79	14.9			
841	2	53	8400	4988	84	2184	420	788	0	282	43.1	4.49	98	13.2			
842	1	61	8800	2924	138	3488	138	138	0	144	44.3	4.61	98	13.9			
843	2	87	6800	2820	112	2820	112	338	0	323	39.0	4.03	97	12.7			
844	2	67	7400	4888	74	2388	222	148	0	241	37.8	4.04	94	12.0			
848	1	58	8700	2948	0	3082	469	201	0	217	42.0	4.88	90	13.2			
848	2	63	3700	999	148	2408	111	37	0	232	34.6	3.84	98	11.8			
861	2	78	8100	2888	81	1832	387	204	0	219	39.4	4.02	98	12.1			
864	1	60	7800	3344	0	3724	228	228	0	227	43.2	4.81	90	13.9			
868	2	52	9300	4743	279	3182	888	888	0	279	43.8	4.47	98	14.0	6.90		
887	2	87	10800	4880	432	4880	218	432	0	338	44.8	8.00	90	18.2	2.80		
888	1	62	4400	2080		1780	80	80	40	218	43.0	4.88	94	14.8			
879	2	30	8800	8188	0	2890	340	88	0	308	49.8	8.47	91	12.8			
880	1	83	12000	7800	600	2780	600	240	0	211	48.3	4.47	104	13.8			
881	1	83	6800	3740	88	2884	408	0	0	228	48.8	8.14	91	14.7			
882	1	62	6400	3778	0	2388	0	288	0	244	47.4	8.70	83	14.8			
898	2	48	8800	3384	232	1972	232	0	0	281	40.7	4.87	89	13.8			
911	2	33	8800	4002	174	1480	88	118	0	280	32.2	3.38	98	11.0			
917	1	66	8000	6200	80	2400	240	80	0	224	38.8	4.27	88	11.7	8.20		
919	1	38	8300	2388	83	2438	212	212	0	378	38.7	4.19	88	12.0			
920	1	84	8300	2014	189	2844	212	371	0	191	48.0	4.97	97	14.8			
922	2	62	8700	2223	87	2907	171	342	0	200	43.3	4.80	94	13.4			
928	2	38	9800	6988	288	2090	888	478	0	288	38.8	4.49	88	12.8			
928	2	73	8200	3038	310	1922	248	882	0	198	32.4	3.31	98	10.3			
931	1	32	8800	4818	0	3384	344	88	0	438	48.3	8.11	91	18.7			
932	2	61	6400	3988	64	1728	64	878	0	327	38.8	3.79	94	11.8			
934	2	61	8100	2884	122	2989	183	122	0	248	42.0	4.88	88	13.8			
938	2	83	10000	8800	700	2800	600	200	200	179	40.1	4.84	87	14.0	3.30		
941	2	86	8800	8440	0	2880	170	340	0	244	37.4	4.03	93	12.9			
942	2	71	7800	4940	488	1900	488	228	78	208	40.7	4.23	98	12.9	2.90		
943	1	88	9200	4878	184	2300	738	920	184	410	43.7	4.37	100	14.8			
944	1	61	9100	4880	273	2912	837	182	0	228	48.8	8.43	88	18.0	3.20		
960	2	39	11800	6138	890	4484	384	238	0	333	48.3	8.24	88	18.1			
968	2	33	10400	8884	208	2800	820	208	0	224	39.8	4.28	94	12.7			
968	2	77	8800	3380	0	2340	488	328	0	284	38.8	3.89	94	11.8			
969	2	37	8800	2880	220	2038	278	110	0	321	41.2	4.89	88	13.8			
980	2	34	11800	8880	118	1888	890	384	0	283	38.2	3.88	91	11.4			
983	1	89	8900	3127	118	2124	298	238	0	248	41.8	4.80	93	13.1			
988	2	42	8300	4731	884	2188	332	332	83	388	37.7	4.28	89	12.1			
988	1	84	8800	2808	0	2038	110	498	88	249	43.4	4.37	99	13.8			
989	1	89	12800	8378	800	2780	800	800	0	418	37.0	3.82	97	10.4			
970	2	73	8800	4848	0	3148	428	88	0	284	34.8	3.88	94	10.8			
971	1	43	8800	3828	0	4214	818	344	0	291	41.4	4.72	87	14.1			
977	2	40	8700	2907	87	2337	288	114	0	197	39.7	4.49	88	13.0			
980	2	33	7400	4882	0	2294	298	148	0	248	41.8	4.83	90	13.8			
981	1	32	7400	4292	0	2980	148	0	0	248	84.7	8.89	93	18.1			
988	2	38	8000	8840	0	1800	400	180	0	198	37.8	4.19	89	12.8			
1001	2	88	7800	4104	182	3040	304	0	0	372	41.0	4.98	83	13.8			
1007	1	78	8800	2744	88	2382	188	280	0	181	41.8	4.88	89	12.9	2.80		

5004132

COMPUTER LISTING OF 1985 RAW DATA																	
PID	SEX	AGE	WBC	PMN	BAND	LYMPH	MONO	EOS	BASO	PLT	HCT	RBC	MCV	HGB	TSH	PRL	T4
1035	2	34	8000	4000	80	3440	480	0	0	425	42.7	4.74	90	14.8			
1043	2	80	8300								158	44.8	8.23	88	11.9		
1800	1	68	8700	3819	134	2211	402	134	0	260	38.3	3.98	91	11.7			
1808	2	48															
1819	1	43	7700	4312	154	2896	482	77	0	228	52.2	5.49	95	18.2	3.20		
1820	2	68	7200	4392	144	2232	380	72	0	324	44.0	5.11	88	14.8			
1830	2	39	3900	2087	117	1092	78	548	0	140	40.8	4.68	89	13.8			
1841	2	58	8800	2900	0	2282	348	290	0	172	39.3	4.27	92	13.1			
1842	2	33	8400	3024	252	4482	420	252	0	288	48.8	5.80	80	18.6			
1848	1	72	8500	3188	88	3280	0	0	0	182	61.1	6.41	95	18.8			
1848	2	44	12700	7493	381	3937	254	638	0	328	38.1	4.18	92	13.2			
1849	1	32	8800	2992	88	3198	478	88	0	284	44.8	4.88	91	14.7			
1852	1	68	7100	4970	71	1778	284	0	0	300	43.1	4.77	90	14.3			
1853	1	34	8400	2970	84	1838	218	84	0	288	45.8	4.78	98	18.0			
1858	2	43	8100								41.8	5.85	81	18.7			
1868	2	41	8200	3840	38	1824	82	114	0	253	44.8	4.34	89	12.8			
1868	2	38	8000	4080	480	2980	400	180	0	381	38.9	4.33	83	12.2	4.20		
1869	2	33	8800	3440	0	3870	818	774	0	252	42.4	5.22	81	12.8			
1880	2	63	9200	3220	184	6080	92	844	0	208	44.8	4.81	97	14.8			
1881	2	69	8700	2747	0	3082	134	870	87	380	39.1	4.01	98	13.0			
1883	1	60	7000	3780	0	2880	420	140	0	284	45.8	4.73	96	14.8			
1884	2	37	8900	3480	0	3108	278	89	0	227	41.2	4.87	88	13.4	2.70		
1889	2	31	8800	3740	0	2618	408	138	0	208	38.8	4.28	91	13.2			
1870	2	68	8500	3998	0	3828	810	170	0	322	43.0	4.88	88	14.3			
1872	1	38	8200	2788	82	2132	104	188	0	214	49.8	5.48	91	18.3			
1873	1	38	8800	4782	88	3520	88	382	0		49.8	5.23	98	18.6	3.00		
1877	2	38	9800	4898	98	3840	480	288	0	307	38.7	4.21	92	13.3			
1878	2	61	9300	8048	278	2328	888	93	0	382	48.2	6.39	86	14.8			

5004133

34

COMPUTER LISTING OF 1988 RAW DATA

PID	SEX	AGE	WBC	PMN	BAND	LYMPH	MONO	EOS	BASO	PLT	HCT	RBC	MCV	HGB	TSH	PRL	T4	TPR	ALB	GLOB	A/G	CAL
2	1	34	8400	2680	84	3284	128	384	0	268	48.0	4.89	98	14.8	0.00			8.2	4.20	4.0	1.0	10.2
3	1	34	11700	8889	234	3810	488	819	0	238	48.7	8.10	90	18.8	244.00	30.4	8.8	8.3	4.00	4.3	.9	9.7
4	1	71	7800	3118	0	3878	304	304	0	300	48.8	4.99	92	18.8	4.20			8.1	4.10	4.0	1.0	8.8
6	1	34	8900	2419	0	2637	364	472	118	270	39.2	4.22	93	13.3	32.10		8.8	7.2	3.90	3.3	1.2	
7	1	87	4300	1189	0	1849	268	268	268	200	40.3	4.40	92	13.8	.20		7.8	8.1	3.30	4.8	.7	9.5
9	1	83	8900	3381	0	3038	207	138	138	183	48.9	4.79	98	14.7	2.70	1.8		7.8	4.10	3.4	1.2	10.0
10	1	88	8700	4221	87	1878	338	87	134	218	42.2	8.08	83	14.3	0.00			7.7	3.90	3.8	1.0	10.0
12	2	49	8200	4920	0	2870	184	248	0	270	38.8	4.28	90	13.4	3.90			7.6	3.90	3.8	1.1	9.4
14	2	87	8800	3088	0	2928	198	280	88	220	37.4	3.87	97	12.8	4.20			7.8	3.90	3.9	1.0	9.8
16	2	40	11300	8783	113	4407	791	113	113	408	43.3	4.70	92	13.3	.30			8.1	3.80	4.3	.9	9.3
18	1	72	8300	2788	0	2087	371	83	83	248	42.8	8.70	78	13.0								
17	2	38	8400	8828	84	1848	262	888	0	188	43.8	4.89	93	13.3				7.8	3.80	3.8	1.0	8.8
18	2	84	7400	3478	0	3330	222	298	74	418	40.8	4.83	89	14.0	4.40	18.3	7.4	7.8	4.20	3.8	1.2	9.8
19	1	38	4800	3120	0	1104	240	338		240	48.8	8.97	78	14.2	8.80							
20	1	39	13700	11808	0	1233	888	274	0	268	49.8	8.74	88	18.8	3.40			8.1	4.20	3.9	1.0	10.2
21	2	38	8900	3933	0	2891	89	89	0	283	38.7	4.82	81	12.3			12.7	7.3	4.00	3.8	1.1	8.7
22	2	48	8800	3188	0	2888	280	390	0	328	39.8	4.04	98	13.0	3.80			7.9	3.80	4.3	.8	9.5
24	2	48	8100	3819	81	1173	288	102	0	220	44.2	4.78	93	14.4	4.80			8.0	3.80	4.4	.8	9.8
27	1	89	10800	3888	0	8188	848	108	0	288	49.1	4.91	100	17.0	.80			8.3	3.70	4.8	.8	9.8
33	2	34	8800	4312	88	3784	362	284	0	338	40.8	4.28	98	13.4	81.80	14.9		8.1	3.70	4.4	.8	9.4
34	2	77	8300	2394	0	3402	318	128	0	203	38.0	3.88	103	11.8	8.20			7.8	3.40	4.4	.8	9.8
35	1	48	4800	2790	0	1380	180	180	0	220	44.3	4.40	101	18.1	0.00	4.8		7.8	4.00	3.4	1.2	9.3
38	1	40	7700	4188	0	3080	231	0	0	243	48.7	4.84	101	14.7	4.00		1.8					
37	1	83	8400	2882	84	2378	0	432	0	208	42.3	4.22	100	13.8	2.80	1.8	7.8	7.2	3.80	3.4	1.1	9.7
39	2	47	8800	2840	0	2970	398	0	0	828	38.1	4.81	94	13.3	8.80			8.2	3.80	4.8	.8	9.5
40	1	82	8000	2820	0	2820	240	80	80	308	43.2	4.84	98	13.8	3.80			8.1	3.40	3.2	1.1	9.2
41	1	74	8300	8881	0	2873	83	83	0	270	37.9	3.88	98	12.8	3.40			8.2	3.80	4.7	.7	9.8
42	2	38	8200	4810	0	3198	248	248	0	203	43.3	4.32	100	14.8				8.0	3.80	4.2	.9	9.7
44	1	37	8800	3900	0	1980	488	88	130	210	48.8	8.89	82	18.8	2.80		9.2	7.7	3.70	4.0	.9	9.2
47	1	41	8000	2940	0	2820	180	300	80	183	48.8	4.48	102	18.8	3.80	4.8		8.8	4.10	4.8	.9	10.1
49	2	49	8800	1488	0	3878	110	278	88	300	41.4	4.74	87	13.8	2.90		9.4	8.8	4.10	4.7	.9	
81	2	41	8200	3890	0	3772	184	874	0	243	43.2	4.82	94	14.8	12.80			7.1	3.80	3.8	1.0	9.8
83	2	88	7000	3010	0	3430	280	210	70	183	40.9	4.30	98	13.7	1.30			7.3	3.70	3.8	1.0	10.1
84	2	83	4700	4002		2418	89	414		187	33.0	3.43	98	11.3	.70	3.3	10.8	7.8	3.80	4.2	.8	9.8
88	2	34	4700	3431		848	282	47	94	313	22.7	2.48	92	7.9	48.80		7.7	7.3	3.20	4.1	.8	8.8
88	2	82	7000	2240	0	3990	210	490	70	238	38.7	4.17	93	12.9	9.80		9.8	7.8	3.80	4.0	.9	9.1
87	2	48	7200	3098	0	3188	804	144	144	388	39.4	4.34	91	13.8				7.8	3.80	3.7	1.0	9.4
71	2	89	8800	3870	0	4300	88	344	0	213	38.2	4.03	98	13.8	4.00			8.2	3.70	4.8	.8	9.1
72	2	40	9700	8828	97	2910	388	882	97	380	37.8	3.91	98	11.8	18.80			7.8	3.20	4.8		10.1
73	1	81	8900	2419	89	3009	413	0	0	238	48.8	4.98	93	14.7	.40	4.2	18.3	7.7	4.00	3.7	1.1	9.4
74	2	49	8100	3402	81	3078	408	1134	0	310	48.9	8.22	88	18.2				7.9	3.80	4.4	.8	9.1
78	2	44	13100	7880	131	3144	824	1834	131	298	40.8	4.43	91	13.8	11.80			8.3	3.80	4.8	.8	9.5
78	1	43	8000	2040	0	3240	240	480	0	188	48.1	4.84	97	14.8	4.40	3.3						
77	1	87	7800	4788	0	1824	780	228	0	288	47.8	8.28	90	18.1	4.80			8.0	3.40	4.8	.7	10.0
78	2	88	7400	3700	0	3404	148	74	0	408	40.9	3.98	103	13.9	8.40			8.1	4.00	4.1	1.0	
79	1	72	8300	4410	0	1449	318	83	83	178	49.4	8.20	98	18.8	2.70		9.8	7.4	3.80	3.8	1.0	8.9
88	1	31	8800	4902	0	2838	818	344		238	48.8	4.98	94	18.8	2.00							
88	2	32	8800	3028	0	2090	220	110	88	278	33.7	4.10	82	10.9	3.90			7.8	3.90	3.7	1.1	
8	1	34	8900	3248	0	2301	238	118	0	333	42.0	4.11	98	14.3	3.40			8.2	4.40	3.8	1.1	9.4
8	2	34	8200	3828	82	3884	184	492	82	280	40.9	4.40	93	13.8	.10	24.8		7.8	3.80	4.0	.9	9.8
48	2	88	8400	2288	108	2322	324	324	0	318	38.0	3.88	93	12.2				7.7	3.80	4.2	.8	9.9
48	2	38	8400	3778	84	2048	320	84	128	218	41.1	4.17	99	13.3	3.80			7.2	3.80	3.7	1.0	9.2
83	2	40	9400	4812	0	4324	420	0	94	373	43.9	4.88	90	14.9	9.20	18.2		7.8	3.80	4.2	.9	9.8
70	2	49	8400	2430	0	1998	270	848	84	230	39.2	4.81	87	13.0				8.3	4.00	4.3	.9	9.8

5004134

COMPUTER LISTING OF 1988 RAW DATA																							
PID	SEX	AGE	WBC	PMN	BAND	LYMPH	MONO	EOS	BASO	PLT	HCT	RBC	MCV	HGB	TSH	PRL	T4	TPR	ALB	GLOB	A/G	CAL	
2102	1	43	8900	3857	0	2822	483	89	89	320	50.8	5.28	97	16.0				7.3	4.00	3.3	1.2		
2103	1	76	8100	3172	308	1952	366	308	0	280	41.7	4.22	99	13.8				7.9	3.90	4.0	.9		
2104	2	66	4800	1920	0	2400	338	98	48	298	38.1	3.93	97	12.3	6.40			8.0	4.80	3.4	1.4		
2106	1	78	8000	6892		2781	721	103	103	492	40.8	4.89	88	14.3				8.1	4.10	4.0	1.1		
2108	1	36	18700	10888	187	4178	1002	801	0	290	49.1	5.88	87	16.4									
2107	2	68	14400	7778	0	4898	1008	878	144	240	44.1	4.88	91	13.7				8.8	4.70	4.1	1.1		
2110	1	80	8900	3363	0	1888	384	298	0	348	37.9	3.83	104	12.3				7.8	3.90	3.9	1.0		
2111	2	38	10800	6184	218	3888	1080	324	108	803	44.8	5.27	84	14.7				9.4	4.80	4.9	.9		
2113	2	37	8000	3480	80	1800	240	360	80	383	41.9	5.12	82	13.1				7.8	3.90	3.8	1.1		
2114	1	73	6400	3840	128	1792	320	288	0	288	48.9	5.39	87	14.4				8.3	4.00	4.3	.9		
2117	2	87	9100	8187	0	2912	384	837	0	310	49.0	6.18	98	14.7				8.8	4.20	4.3	1.0		
2119	2	81	8300	3488	0	2142	282	378	83	288	43.8	4.84	90	14.1				8.1	4.10		1.0		
2123	1	46	7200	6112	0	1812	288	288	0	223	48.8	4.82	99	14.4				8.2	4.10	4.1	1.0		
2128	1	68	8400	2784	0	1728	694	218	108	288	48.0	4.72	98	18.2	3.00								
2128	2	41	7300	3723	0	3088	148	292	73	318	39.9	4.44	90	13.2				7.8	4.20	3.4	1.2		
2129	2	80	8700	2144	87	3018	870	804	0	388	40.8	6.08	80	13.4									
2130	2	38	9300	3834	0	2883	681	2232	0	208	38.7	4.09	90	12.1				8.4	4.10	4.3	1.0		
2132	2	33	4800	2748	48	1218	138	380	0	273	42.4	4.94	88	13.3									
2134	2	33	8300	8229	83	2490	188	332	0	318	41.8	4.84	89	13.7				7.8	3.70	3.9	.9		
2138	1	37	7200	3818	0	2892	432	380	0	308	47.4	4.89	97	18.0				7.0	3.90	3.1	1.2		
2137	1	48	8100	3880	0	1789	308	388	0	228	48.8	5.38	91	18.8				8.7	4.80	4.1	1.1		
2138	2	38	10300	6180	103	2878	309	103	0	438	37.8	4.18	91	13.8				8.8	4.20	4.3	1.0		
2139	2	68	8400	1812	0	3828	448	112	0	348	43.8	3.88	98	13.8	6.80			7.8	4.00	3.8	1.1		
2140	2	79	7900	4774	0	2079	231	308	308	188	30.9	3.38	92	10.0				7.2	3.80	3.8	1.0		
2142	1	38	10900	6887	0	3379	109	218	218	288	47.3	4.92	98	18.8				7.2	3.70	3.8	1.0		
2143	1	38	8700	3891	87	1482	488	114	87	308	44.8	6.18	88	18.1				7.7	4.00	3.7	1.1		
2144	1	39	8400	4388	0	3812	420	0	0	180	63.7	6.47	98	17.1				7.9	4.40	3.8	1.3		
2148	1	68	8400	3294	0	1488	432	182	84	308	42.8	4.33	98	13.9	2.00			7.9	4.00	3.9	1.0		
2147	2	37	7300	4872	0	2283	292	73	0	313	40.7	4.88	89	13.7				7.7	4.00	3.7	1.1		
2148	1	77	8100	4131	0	2838	810	243	81	223	39.3	4.17	94	13.2	3.90			7.7	4.00	3.7	1.1		
2149	2	41	8700	2813	0	3380	201	402	134	288	39.0	4.14	94	12.8				7.7	3.90	3.8	1.0		
2180	1	48	8300	8083	0	2822	249	188	0	218	47.1	6.43	87	14.8	1.00								
2182	1	60	8800	3248	110	1378	278	498	0	300	48.8	6.08	98	18.8				8.8	4.40	4.1	1.1		
2188	1	33	9300	6138	0	2790	93	279	0	388	49.2	6.82	88	18.8				7.9	4.80	3.3	1.4		
2188	1	42	8200	3938	184	3890	410	0	0	230	68.7	8.70	98	17.4				7.0	4.10	2.9	1.4		
2188	2	82	8800	2240	0	3080	188	88	88	310	39.8	4.40	90	13.0				8.4	4.10	4.3	.9		
2189	2	38	7800	3878	0	2984	380	380	0	410	42.9	4.80	93	14.3				7.8	4.20	3.8	1.2		
2180	2	37	8800	2282	88	2494	290	880	0	370	48.4	6.04	90	14.9	8.10			8.2	4.10	4.1	1.0		
2182	2	68	9200	3884	92	4140	0	1104	0	378	40.8	4.88	89	11.8	4.10			8.9	3.80	8.3	.7		
2188	1	43	8200	3444	0	3938	874	82	184	332	44.4	6.00	89	14.8				8.3	4.30	4.0	1.1		
2188	1	70	8800	3840	0	1344	280	338	0	223	41.1	4.38	98	13.0	3.10			7.2	3.80	3.8	1.0		
2187	1	47	7100	3479	71	2911	284	284	71	313	43.8	4.81	91	18.8				7.4	4.00	3.4	1.2		
2171	2	38	8200	6412	0	2214	248	328	0	278	42.3	4.88	91	13.4	.80			7.8	3.80	4.0			
2172	2	48	8900	3884	0	2883	207	207	89	403	44.9	4.92	91	13.7	2.30			7.8	3.80	4.0	.9		
2174	1	33	8800	8280	0	1848	1088	818	0	370	49.3	8.38	92	18.8				8.0	4.40	3.8	1.2		
2178	1	43	8800	3804	88	2884	478	204	0	380	47.9	4.87	98	14.8	1.20			9.8	6.30	4.2	1.2		
2182	2	88	8300	2173	0	2882	288	0	0	283	37.8	4.02	94	12.1	2.80			8.8	4.80	4.3	1.0		
2188	1	38	8700	2808	0	1710	884	827	114	200	80.3	8.80	91	18.3									
2189	2	69	8400	8300	188	924	840	188	0	330	21.9	2.34	94	7.7				7.2	3.30	3.8	.8		
2193	2	84	8800	3898		1824	88	224	283	31.8	3.34	94	10.4	2.80				7.3	3.80	3.8	1.1		
2198	2	87	8800	3840	130	2278	130	280	88	343	41.2	4.88	88	13.8	2.10			7.8	4.20	3.3	1.3		
2198	2	71	8800	3300	0	2310	198	792	0	218	40.8	4.49	90	13.4	10.00			8.3	4.40	3.9	1.1		
2197	2	34	7200	3188	72	3488	288	72	144	298	39.8	4.48	89	12.9	4.00			7.9	4.20	3.7	1.1		
2208	1	82	9800	4488	0	4780	288	0	0	330	47.9	8.48	88	13.7				7.4	3.70	3.7	1.0		

5004135

36

PID	SEX	AGE	WBC	PMN	BAND	LYMPH	COMPUTER LISTING OF 1986 RAW DATA							TSH	PRL	T4	TPR	ALB	GLOB	A/G	CAL
							MONO	EOS	BASO	PLT	HCT	RBC	MCV								
2208	1	66	8500	4878		2978	810	170	170	240	45.3	4.06	92	14.4				7.7	3.80	3.9	1.0
2207	1	36	7000	3010	0	3500	0	420	70	288	44.8	5.18	87	13.9				8.0	3.80	4.2	.9
2208	2	70	10800	6264	0	3240	216	664	216	360	40.9	4.47	91	13.9				8.1	3.60	4.5	.8
2209	2	36	9300	6766	93	2139	93	930	279	488	36.3	4.07	89	12.8				7.9	3.70	4.2	.9
2210	2	33	9800	7410	0	1620	478	98	0	273	39.9	4.22	95	12.4				7.2	3.20	4.0	.8
2212	2	67	8100	4638	0	2784	182	667	81	293	26.9	2.98	90	8.9	2.80			6.0	2.30	3.7	.6
2213	2	34	8300	3652	0	3984	249	416	0	373	39.0	4.40	89	12.6				8.1	3.80	4.3	.9
2216	2	66	7800	3800	0	2736	380	664	0	348	47.6	5.63	84	14.7				8.1	3.70	4.4	.8
2216	2	67	9000	6210	0	2280	90	380	90	448	36.3	4.29	88	12.9				8.6	3.30	5.3	.6
2217	2	64	6600	3366	132	2640	132	330	132	253	44.1	4.46	99	14.2				8.6	3.70	4.9	.7
2220	2	66	6700	2166	87	3138	0	342	0	273	43.8	4.63	95	14.6				8.6	4.60	4.0	1.1
2221	2	66	6700	3192	0	1998	399	114	0	273	38.7	4.01	97	12.3	4.10			7.7	3.30	4.4	.7
2224	2	64	7100	4618	213	1917	358	0	0	298	34.0	3.56	96	11.2				7.9	4.30	3.6	1.2
2228	2	39	6800	6008	130	978	66	198	130	232	28.1	3.13	90	9.4	0.00			7.6	3.30	4.3	.6
2226	2	34	6900	3658	69	1662	296	118	118	288	36.8	4.17	86	12.1	2.00			7.0	3.30	3.7	.9
2227	2	37	10200	6630	0	2448	612	408	102	478	27.6	3.72	74	9.1				7.4	3.20	4.2	.6
2228	2	41	11800	6380	0	3628	680	696	116	460	42.0	4.72	89	13.2				9.2	6.00	4.2	1.2
2229	2	61	8200	6248	82	2060	674	246	0	348	41.1	4.46	92	13.7				7.1	3.80	3.6	1.0
2230	2	46	7200	4638	144	1872	72	678	0	283	42.3	6.06	84	14.4	1.60			8.0	4.40	3.6	1.2
2231	2	34	6700	6666	87	1740	348	0	261	668	44.4	6.26	84	14.7				8.6	4.40	4.2	1.0
2232	1	36	8800	3608	0	3672	792	440	88	228	51.4	6.32	97	16.7	6.80			7.4	4.10	3.3	1.2
2233	1	33	8500	4808	88	3486	88	340	0	268	51.0	6.44	94	17.3				8.7	4.60	3.9	1.2
2236	1	40	6700	3360	0	2614	67	402	67	268	48.6	6.26	92	14.7				7.8	4.30	3.6	1.2
2236	1	44	9200	6428	0	3668	0	92	92	236	42.6	4.97	86	14.9				8.8	4.60	4.3	1.1
2237	1	39	6300	2772	0	2961	378	63	126	363	42.6	4.66	93	14.3				8.0	4.40	3.6	1.2
2239	2	36	6300	2703	0	2014	106	477	277	33.0	3.73	88	11.2	3.20				8.0	4.40	3.6	1.2
2242	1	33	6700	3308	0	1663	399	288	67	248	51.3	6.61	93	16.9				8.0	4.60	3.6	1.3
2244	2	77	6000	2400	60	2080	60	460	0	270	40.6	4.09	99	12.3				8.1	3.70	4.4	.9
2246	1	33	7700	2698	0	3880	647	231	77	300	60.1	6.18	97	16.1				7.8	4.60	3.3	1.3
2247	2	41	6200	4610	0	2706	738	246	0	310	39.6	4.29	92	12.7				7.7	3.90	3.6	1.0
2248	2	48	6900	3916	0	2648	448	1613	178	248	46.0	6.46	83	13.7				8.1	4.20	3.9	1.1
2260	1	43	6600	3784	0	3670	268	602	86	383	47.1	6.38	88	16.6				7.7	4.80	2.9	1.6
2261	2	36	10200	6428	0	2668	308	610	102	396	37.6	4.98	78	12.6				8.2	4.00	4.2	1.0
2264	2	37	6800	3074	0	1740	174	696	116	410	34.3	4.66	74	10.7				8.3	3.80	4.6	.9
2266	2	33	7400	3922	0	2886	296	74	222	183	43.0	4.62	89	13.8				7.1	3.60	3.6	1.0
2266	2	36	6400	2944	128	3328	0	0	0	300	36.4	4.23	91	12.8				7.3	3.60	3.7	1.0
2267	1	40	6900	4968	69	1380	278	138	69	283	46.6	6.66	82	16.6				7.9	4.40	3.6	1.4
2260	2	33	6300	3486	166	3984	332	332	0	406	42.2	4.46	98	14.3				7.6	4.10	3.6	1.2
2261	1	66	6200	3224	104	1404	416	62	0	218	46.3	6.13	94	16.2				8.0	4.30	3.7	1.1
2269	1	32	13200	9372	0	3036	660	132	132	263	46.7	6.00	97	16.6				7.6	4.40	3.2	1.4
2271	1	32	7900	2923	0	3960	711	316	0	296	46.6	6.39	90	16.9	3.60			8.6	6.00	3.6	1.4
2273	1	33	7100	2414	0	3908	639	142	0	310	49.7	6.69	84	17.1	1.20			8.6	4.90	3.6	1.3
2274	1	32	7800	3268	76	3724	380	78	76	473	47.8	6.41	87	16.4				8.1	4.60	3.6	1.2
2276	1	33	10200	3678	0	6610	102	408	204	308	53.0	6.78	92	16.1				9.6	6.60	4.0	1.4
806	2	33	7800	4624	234	2108	312	624	0	343	36.4	4.00	88	11.3				6.7	3.20	3.6	.9
812	2	32	6600	6290	1360	426	340	66	0	200	30.7	3.30	93	10.6							
816	2	37	6200	2704		1924	104	416	62	143	32.2	3.93	82	11.1				6.7	3.70	3.0	1.2
821	2	36																6.6	3.30	3.3	1.0
823	1	43	6700	4266	0	1943	201	201	67	186	42.6	4.46	96	14.4				7.0	4.00	3.0	1.4
826	2	46	7000	2660	0	4060	260	0	0	260	39.7	4.61	86	13.6				8.0	3.70	4.3	.9
826	2	60	4400	2200	132	1320	396	362	0	218	39.6	4.29	92	12.3				9.2	4.00	6.2	.6
829	2	49	6800	3468	0	3060	204	0	68	420	36.0	3.69	93	12.6				8.7	3.80	4.9	.8
830	1	46	6600	4964	204	884	204	644	0	203	42.7	4.39	97	16.0				7.2	3.70	3.6	1.1
831	1	46	9300	3634	0	4667	668	372	279	323	46.6	4.67	93	16.6				8.3	3.70	4.6	

5004136

37

COMPUTER LISTING OF 1988 RAW DATA																							
PID	SEX	AGE	WBC	PHN	BAND	LYMPH	MONO	EOS	BAZO	PLT	HCT	RBC	MCV	HGB	TSH	PRL	T4	TPR	ALB	GLOB	A/G	CAL	
832	2	49	6400	2692	0	2538	182	108	0	328	37.8	4.83	82	12.8				7.8	3.90	3.7	1.0		
833	1	64	6500	1980	0	3025	330	110	66	346	44.6	6.16	86	14.6				7.6	3.90	3.8	1.1		
834	1	63	6300	4221	0	1764	189	126		212	46.7	6.33	88	16.8									
836	2	63	9300	3266	0	6394	186	372	93	203	43.6	4.64	96	16.1				7.6	3.60	4.0	.9		
840	1	66	6600	4664	0	2376	704	1066	0	196	46.4	6.82	80	16.2				8.1	4.10	4.0	1.0		
841	2	64	9700	6432	97	2910	873	366	0	263	36.3	3.90	93	12.3				8.2	3.70	4.6	.8		
843	2	66	6600	2640	0	1980	366	440	66	236	40.6	4.26	96	12.8				7.3	3.30	4.0	.8		
844	2	66	6200	2608	0	2028	364	0	0	210	38.0	3.99	96	12.7				8.6	4.00	4.6	.9		
846	1	67	9100	4469	0	3622	726	91	0	290	42.6	4.63	92	13.6				7.3	3.70	3.6	1.0		
848	2	63	1800	306	0	1366	0	64	0	164	21.0	1.96	108	6.4									
851	2	77	6400	2764	64	2106	106	106	0	293	36.6	3.67	97	12.7				7.8	3.60	4.2	.9		
863	1	36	6600	3066	0	3066	260	66	66	290	64.0	6.49	96	17.6				7.6	3.70	4.1	.9		
864	1	60	6400	2944	0	2816	192	446	0	228	46.1	6.06	89	14.3									
866	2	62	6600	2924	0	3264	406	204	0	220	44.2	4.64	96	14.3	2.40			7.8	4.20	3.6	1.2		
867	2	66	7300	2774	73	4161	146	73	73	343	46.2	6.06	91	16.7				7.9	3.80	4.3	.8		
881	1	64	6400	4704	0	3444	166	0	64	263	42.4	4.79	89	14.6				7.8	3.60	4.3	.8		
882	1	64	6000	4000	0	2860	60	1040	0	276	46.4	6.69	83	16.0				7.6	3.60	4.0	.9		
883	1	76	7000								46.0												
886	2	67	10000								46.0												
891	2	36	6600	2990	0	3066	130	260	66	363	46.7	4.93	96	14.6				7.6	3.60	4.0	.9		
896	2	47	3900	2608	39	666	273	76	117														
911	2	34	6600	3762	0	1232	166	392	66	306	39.0	4.30	91	13.1				7.6	3.60	3.7	1.0		
914	2	62	9600	4214	0	4018	392	1076	96	120	34.1	3.81	89	11.2				7.3	3.60	3.6	1.1		
917	1	66	7000	4200	70	2360	70	260	0	236	39.6	4.49	86	12.4	3.00			6.9	3.40	3.6	1.0		
919	1	36	6100	2148	0	2193	610	163	102	266	42.4	4.63	86	13.7				6.3	3.70	4.6	.8		
920	1	66	6200	2294	0	2976	166	744	0	176	46.9	4.64	96	16.6				6.6	3.90	4.9	.8		
926	2	74	6600	4821	441	1260	262	126	0	270	36.7	3.72	96	10.6				9.0	3.70	6.3	.7		
931	1	33	13200	7666	0	4366	792	396	0	236	60.6	6.90	103	19.6				7.4	4.10	3.3	1.3		
932	2	62	7600	4070		2664	146	616		262	37.6	4.09	92	12.7				8.1	3.70	4.4	.8		
934	2	62	6100	2606	61	2379	0	163	0	306	46.2	6.46	64	14.3				7.9	3.70	4.2	.9		
936	2	64	6400	4224	0	1664	64	364	64	196	41.2	4.63	89	13.1				8.1	3.70	4.4	.8		
939	1	41	6600	3666	0	4260	0	426	170	320	43.6	4.76	92	14.6				7.7	3.90	3.6	1.0		
942	2	72	4900	2206	0	2646	147	147	0	216	36.1	4.04	94	12.9				7.4	3.60	3.6	.9		
943	1	66	9400							203													
944	1	62	6000	4140	0	1320	180	240	120	200	60.2	6.66	89	16.4				7.6	4.40	3.2	1.4		
966	2	36	6400	3712	64	1726	266	676	64	303	36.6	4.12	94	12.6				7.8	4.00	3.6	1.1		
966	2	77	7400	3996	74	2960	146	222	0	313	36.9	3.60	94	11.6				7.4	3.90	3.6	1.1		
966	1	66	6900	3627	176	3736	366	712	69	296	36.7	4.01	92	12.4				7.9	4.30	3.6	1.2		
969	2	37	6700	3016	67	2077	266	1139	0	260	40.6	4.66	86	13.6				7.2	3.90	3.3	1.2		
960	2	36	13100	7336	131	4976	262	393	0	403	36.1	4.36	66	12.6				7.9	4.00	3.9	1.0		
966	2	43	7600	4766	162	1672	304	664	0	396	40.1	4.67	66	12.6				7.9	3.90	4.0	1.0		
966	1	66	6000	2900	60	1660	100	400	0	193	40.0	4.26	96	13.0				7.6	4.20	3.3	1.2		
971	1	44	7600	3364	76	3610	466	390	0	373	46.7	6.26	92	16.4				6.7	6.20	3.6	1.6		
977	2	40	6100	3646	61	2916	243	1134	61	273	46.1	6.19	89	16.1				8.6	4.20	4.4	.8		
980	2	34	11400	7162	0	3420	466	226	114	263	46.3	6.12	90	14.0				7.7	4.00	3.7	1.1		
981	1	33	4400	2266	0	1692	132	66	0	196	43.7	4.77	92	16.0				7.2	4.30	2.9	1.6		
996	2	39	9300	6962	93	2790	372	93	0	166	39.6	4.39	91	13.4				7.2	.34	3.6	.9		
1001	2	63	6700	3149	0	2614	636	201	0	323	44.0	6.26	84	14.4				8.2	4.40	3.6	1.2		
1007	1	76	6100	2764	0	2091	163	102	0	296	39.9	4.36	91	13.6				7.6		3.6	1.1		
1600	1	66	6100	3643	0	1691	244	122	0	243	34.6	4.02	86	12.1	1.40			7.7	3.80	3.9	1.0		
1619	1	44	6900	3361	0	2622	463	346	69	266	46.6	6.04	91	16.6				7.6	4.20	3.4	1.3		
1620	2	66	6100	1962	0	3699	366	122	61	266	41.1	4.67	64	14.3				7.3	3.60	3.4	1.2		
1624	1	44	10100	2626	0	6666	202	101	101	220	47.6	6.21	91	16.1				7.8	4.40	3.4	1.3		
1626	2	43	6900	3933	69	2663	207	136	0	313	39.7	4.27	93	13.0				7.2	4.00	3.2	1.2		

COMPUTER LISTING OF 1966 RAW DATA																						
PID	SEX	AGE	WBC	PMN	BAND	LYMPH	MONO	EOS	BASO	PLT	HCT	RBC	MCV	HGB	TSH	PRL	T4	TPR	ALB	GLOB	A/G	CAI
1828	1	66	8100	4698	0	2811	243	887	81	308	38.8	4.08	88	12.7				7.8	3.80	3.8	1.0	
1829	1	39	11600	8004	118	2784	232	484	0	183	49.1	8.87	88	18.3				7.4	4.30	3.1	1.4	
1841	2	59	8800	2282	0	3018	174	290	0	338	40.8	4.81	90	12.8				7.8	4.20	3.8	1.2	
1842	2	33	9100	6098	0	3367	848	0	91	208	41.7	8.17	81	14.3				7.1	3.90	3.2	1.2	
1848	1	73	9900	3388	0	8448	99	891	99	210	47.2	4.78	99	18.9				7.2	4.00	3.2	1.2	
1848	2	48	12000	4880	120	2880	480	3120	120	293	41.1	4.80	91	13.2				7.8	3.70	4.1	1.9	
1852	1	87	8800	3878	0	2838	198	198	0	320	46.4	8.18	90	14.8	1.90			10.4	8.90	4.8	1.3	
1883	1	38	10000	8300	100	3700	600	200	200	328	39.4	4.03	98	13.9				8.2	4.70	3.8	1.4	
1888	2	44	8300	8083	0	2888	418	188	0	280	48.8	8.04	80	18.8				7.8	4.20	3.8	1.2	
1888	2	42	4100	2009	82	1888	208	248	0	288	40.2	4.07	99	12.9	8.30			7.4	4.00	3.4	1.8	
1888	2	38	8200	2388	0	2728	882	372	82	248	44.8	4.88	98	14.0	2.40			7.4	3.80	3.8	1.0	
1889	2	34	9000	4080	180	4410	270	90	0	278	40.3	4.89	82	12.4				7.8	3.90	3.9	1.0	
1883	1	80	8000	2820	80	2940	80	120	0	238	47.8	8.18	92	18.1				8.0	4.40	3.8	1.2	
1884	2	38	8200	3938	0	3118	248	902	0	323	40.1	4.42	90	13.8				8.0	3.90	4.1	1.0	
1888	2	38	9800								37.0											
1870	2	68	8800	8072	0	2200	284	284	0	418	48.4	4.98	91	14.3				13.2	8.30	8.9	1.9	
1872	1	38	7400	3882	370	2890	888	148	148	218	80.7	8.21	97	18.8				7.8	4.30	3.2	1.3	
1873	1	38	7800	3828	0	3300	828	180	0		80.8	8.28	98	17.4								
1877	2	38	10400	8818	208	3744	418	418	0	388	48.8	4.80	97	13.8				8.8	4.20	4.4	1.0	

5004138

39

COMPUTER LISTING OF 1987 RAW DATA																			
PID	SEX	AGE	WBC	PMN	BAND	LYMPH	MONO	EOS	BAZO	PLT	HCT	RBC	MCV	HGB	TSH	PRL	T4	FBS	HBA1C
2	1	34	8200	4592	0	2542	164	820	82	225	43.9	4.54	97	15.2			14.8		
3	1	34													44.90				
4	1	71	8800	1972	68	3421	290	0	68	270	43.1	5.02	88	15.5	1.50		229.0	15.7	
5	1	34	8400	1944	0	2538	648	324	0	190	44.3	4.71	94	14.0	51.40				
7	1	67	6100	1525	0	3762	549	183	61	365	39.2	4.16	94	13.1			18.3		
9	1	53	8800	5280	0	2904	264	264	88	175	43.9	4.69	98	15.0	1.50				
10	1	58	8800	4556	0	1536	272	0	138	255	45.0	5.34	85	15.1	.20		8.3	131.0	8.8
12	2	49	8900	2006	118	3540	177	59	0	290	35.1	3.81	92	13.3	1.50				
14	2	57	7100	3053	0	3753	213	71	0	230	36.9	3.72	99	12.9	3.40				
15	2	40	11200	5272	0	3135	754	0	112	325	41.0	4.34	94	13.2	3.40				
16	1	72	6100	2567	61	2867	305	0	0	195	41.1	5.55	74	13.4	.30				
17	2	36	8100	4293	0	3402	81	324	0	290	40.8	4.53	89	14.0					
18	2	54	8800	3400	0	2554	204	612	0	255	35.3	4.12	93	13.2	2.10		14.2		
19	1	38	9100	5916	0	1729	384	0	91	255	41.5	5.57	74	14.4	302.00		92.0		
20	1	39	9000	4500	0	3330	450	630	90	275	45.4	5.44	89	15.1	1.10		10.2		
21	2	35	8200	3535	0	1455	104	104	0	250	33.4	3.91	85	12.1					
22	2	45	5300	2703	0	2120	315	105	105	200	37.1	3.57	95	13.2	.50		105.0		
23	1	36	7200	3500	0	3354	72	144	0	45.0				15.0	7.50				
24	2	45	8800	2310	0	3554	594	66	66	340	42.5	4.55	88	13.5	.20				
27	1	59	9900	3551	0	4059	594	1355	0	145	43.4	4.32	100	15.5			105.0	9.8	
33	2	34	8600	3432	0	2970	132	66	0	320	35.5	4.50	84	13.1	32.50				
34	2	77	8800	5332	0	2535	255	0	88	240	35.4	3.59	104	12.5	10.00				
35	1	40	8300	2394	0	3213	630	63	0	220	37.1	3.95	94	12.5	9.50				
37	1	53	8500	1950	0	3050	55	330	55	203	42.2	4.35	97	14.1	2.10				
39	2	47	7100	4473	0	2343	71	0	213	335	35.7	4.09	95	13.5	2.20				
40	1	52	8100	3507	0	3555	324	81	0	250	39.5	4.15	95	13.7	3.10				
41	1	74	6700	4355	0	1575	535	134	0	205	40.5	4.27	95	13.1	3.40				
42	2	35	11000	7150	220	3410	110	0	110	155	35.5	3.33	105	12.5	3.70				
44	1	37	8400	2555	0	4115	252	1005	155	245	42.1	4.93	85	14.4	5.10		8.7		
47	1	41	8300	3403	0	4057	495	155	155	230	44.4	4.32	103	15.5	.50				
49	2	49													1.50				
51	2	41	7500	4454	0	2555	0	505	0	295	45.3	5.05	90	15.5	.30		349.0		
53	2	55	8500	3540	0	2275	195	195	0	250	35.2	4.13	92	13.5			103.0	3.8	
54	2	53													80.00				
55	2	34	7100	4515	0	1704	539	0	142	270	35.0	3.57	93	11.9	10.50				
56	2	52	7100	3053	71	3337	254	254	71	245	35.0	4.14	92	13.0	3.00				
57	2	45	8500	3595	0	2175	452	195	65	250	35.5	4.11	94	13.5	.50		9.2		
71	2	59	7400	4514	74	2355	74	370	0	230	35.4	4.05	94	13.0	2.50				
72	2	40	5700	3591	57	1524	225	0	0	275	39.0	4.45	87	13.1	131.00				
73	1	51	8500	3594	0	2244	254	195	0	205	45.0	4.51	94	15.2	.10				
74	2	49	10500	5555	0	4033	545	545	105	375	43.9	4.92	89	15.2					
75	2	44	10400	5405	0	3540	415	935	0	295	40.5	4.35	93	13.5	10.50				
76	1	43	8300	2324	0	5475	249	155	83	320	45.0	4.75	95	15.0	2.50				
77	1	57													1.90				
78	2	55	8500	4050	0	3400	550	340	0	235	40.5	4.25	95	12.5	.10				
79	1	72													1.50		137.0		
83	1	32	8500	1550	0	4095	130	715	0	175	45.1	4.77	101	15.5	4.70				
85	2	32	8500	4150	0	1495	325	390	130	240	37.5	4.55	83	12.2	2.40				
8	1	34	5700	2793	0	2223	570	57	57	295	41.7	4.44	94	14.5	2.50				
8	2	34	11300	7910	0	2935	113	339	0	205	42.3	4.31	95	14.5					
45	2	55	7400	4510	74	1924	222	515	74	199	35.2	3.75	95	12.7					
45	2	35	5300	2509	53	2173	105	53	105	250	37.7	3.53	95	13.3	1.50				
53	2	40													.80				
70	2	49	4500	2400	0	1920	45	432	0	175	37.1	4.44	84	12.5					

5004139

COMPUTER LISTING OF 1987 RAW DATA																			
PID	SEX	AGE	WBC	PMN	BAND	LYMPH	MONO	EOS	BASO	PLT	HCT	RBC	MCV	HGB	TSH	PRL	T4	FBS	HBAIC
81	2	41	8100	3848	0	3189	182	1063	81	218	40.0	4.34	92	13.4	.60				
2102	1	43	8100	3888	0	2918	891	243	182	308	44.9	4.88	98	16.8	1.40			87.0	
2103	1	78	18800	12600	672	2620	804	338	188	278	38.8	3.98	98	13.2	1.20			88.0	
2104	2	58	8900	3422	0	1829	931	118	0	218	39.2	4.11	98	13.0	6.00	6.4	121.0	9.4	
2108	1	78	10800	8804	0	2700	788	840	0	408	48.8	4.78	90	14.2	.30				
2107	2	88	18200	8288	0	8988	488	824	182	420	41.2	4.88	89	18.4	2.80			184.0	
2108	1	43	8900	4209	207	2208	138	138	0	378	43.1	4.83	89	18.3	2.10			98.0	
2110	1	80	7300	3723	0	2701	388	388	73	338	38.1	3.37	104	12.3	3.10				
2111	2	38	21700	18278	0	3038	1302	1088	217	188	47.0	8.83	83	16.8	3.00				
2113	2	37	8900	4183	0	4272	287	178	0	340	44.8	8.41	82	14.9	1.90			274.0	10.8
2114	1	73	8200	8822	82	1840	248	184	248	220	41.8	4.71	88	14.4	1.80			280.0	10.8
2117	2	87	11200	8182	0	8040	338	448	0	298	43.7	4.89	93	14.7	3.40			221.0	
2119	2	81	8800	4818	0	3384	172		0	198	43.0	4.71	91	13.7	1.60				
2128	2	41	7800	8182	0	1880	0	0	78	340	38.4	4.22	91	12.8	.70				
2129	2	80	7400	4884	74	1884	370	370	148	288	33.2	4.12	81	12.0	2.90			383.0	10.0
2130	2	38	8100	3880	0	1982	122	388	0	240	38.0	3.87	90	12.0	1.00	12.1			
2134	2	33													1.40				
2136	1	37	7100	2911	0	3880	388	284	0	220	46.8	4.74	97	16.1	1.80				
2137	1	48	8800	3448	0	2800	198	198	88	290	40.4	4.38	93	13.8	1.80				
2138	2	38	7800	8400	0	1878	300	180	0	300	32.4	3.47	93	11.2	1.30				
2139	2	88	8000	3880	0	1880	300	380	0	428	38.2	3.88	94	12.4	4.00				
2140	2	78	8700	3708	0	1839	288	171	0	280	28.0	3.18	91	9.9	8.40				
2142	1	38	8200	4428	0	2842	984	184	0	230	42.3	4.47	98	14.8	1.90				
2143	1	38	14700	8232	0	8174	0	147	147	338	44.4	8.09	81	18.0	3.40			92.0	9.7
2148	1	88	8200	2880	0	1788	280	208	104	278	38.7	3.73	98	12.8	2.00				
2148	1	77	8800	3088	0	2730	390	198	130	228	37.0	3.94	94	12.8	4.30				
2149	2	41	7800	3880	0	3118	78	488	182	280	38.8	4.03	89	12.3					
2180	1	48	8400	8208	0	2438	888	188	0	320	47.8	8.81	88	18.8	1.70			288.0	12.2
2182	1	80	8100	4331	0	1484	244	81	0	220	41.8	4.38	94	14.8	1.30			79.0	
2183	1	34	8800	2888	0	2200	440	188	110	208	41.8	8.08	82	14.0	2.80				
2188	1	33	8900	3088	0	2380	384	118	0	218	43.8	8.11	88	14.9	1.00			100.0	9.4
2188	1	42	8100	2198	0	3899	244	0	81	270	80.8	8.24	98	17.4	.90			89.0	7.9
2188	2	82	8400	2782	0	2944	384	320	0	283	43.4	4.87	90	13.3	1.70				
2189	2	38	7400	4282	222	2220	892	74	0	490	42.7	4.88	88	14.9	1.90				
2180	2	37	8800	3448	0	2340	880	88	0	308	42.3	4.72	90	14.4	8.80			233.0	10.8
2182	2	88	11100	7889	0	2331	888	111	111	290	38.8	4.13	88	12.3	4.30				
2188	1	70	10800	8808	218	4782	218	324	0	228	48.2	8.00	92	18.4	3.80				
2187	1	47	10300	8283	0	4120	824	103	0	218	44.8	8.08	88	18.8	1.10				
2170	1	74																	
2171	2	38	8300	8312	0	2873	332	0	83	238	40.2	4.48	90	13.4		10.3			
2172	2	48	8400	3138	0	2824	448	128	84	440	40.8	4.87	89	13.8	.40			208.0	
2174	1	33	9000	8490	0	2430	720	180	180	280	48.8	8.18	90	18.0	1.80	6.4			
2178	1	43	7300	3889	0	2993	388	73	0	288	43.7	4.82	98	15.1	1.40			187.0	11.2
2182	2	88	8800	3180	0	2288	0	0	88	280	34.3	3.88	94	12.1	2.90	19.9			
2188	1	38	10800	7878	0	1890	738	0	0	318	80.7	8.38	94	18.3	1.70				
2193	2	84	8700	3819	0	1839	0	228	114	328	30.9	3.38	92	10.8	3.70			87.0	
2198	2	87	8700	2907	0	2394	114	228	87	378	37.8	4.49	84	12.8	1.20	9.4			
2198	2	71	7100	4189	0	2789	71	71	0	310	38.4	4.20	87	12.7	.30			124.0	8.0
2197	2	34	8700	3484	0	2880	134	288	134	238	34.7	3.74	93	12.0	1.30				
2208	1	82	8000	4240	0	2980	880	240	0	388	48.0	8.32	88	14.7	1.00			207.0	10.1
2208	1	88	8000	3080	0	2100	800	240	0	240	40.4	4.49	90	14.2	.90				
2207	1	38	8000	3040	0	3780	400	720	80	220	44.7	8.33	84	18.0	1.80			181.0	10.3
2208	2	70	10100	7777	0	1717	101	404	101	288	38.2	3.98	91	12.8	8.80			289.0	13.9
2209	2	38	8400	4838	0	3444	84	338	0	378	37.1	4.18	89	13.1	1.80				

041405

11

COMPUTER LISTING OF 1987 RAW DATA																			
PID	SEX	AGE	WBC	PMN	BAND	LYMPH	MONO	EOS	BASO	PLT	HCT	RBC	MCV	HGB	TSH	PRL	T4	FBS	HBA1C
2210	2	33	12100	9559	121	2178	242	0	0	295	39.8	4.41	90	13.4	1.30				
2212	2	87	26200	24948	0	0	0	262	0	205		1.76			26.80			81.0	
2213	2	34	8300	4648	0	3071	166	332	83	368	33.9	3.83	89	12.2	.90				
2216	2	66	9500	4998	0	3136	392	1274	0	266	40.4	4.89	86	14.0			222.0	10.1	
2218	2	87	9700	8044	0	3589	388	679	0	368	37.8	4.41	85	13.2	1.80			95.0	8.0
2217	2	54	7400	4614	0	2072	296	0	222	260	37.5	4.13	91	13.2	2.00			90.0	8.4
2220	2	58	6600	3630	0	2178	462	198	132	260	38.9	4.09	96	13.6	4.50		4.6		
2221	2	65	8600	8338	0	1462	1462	86	268	390	38.4	4.08	94	13.2	6.40				
2224	2	64	8600	3770	0	1856	58	116	0	378	30.6	3.29	93	10.7	2.30				
2226	2	39	8800	4928	0	3080	628	264	0	238	34.1	3.96	86	11.6	3.90				
2226	2	34	6900	3933	69	2653	276	0	69	224	37.6	4.64	81	12.6	2.80				
2227	2	37	7300	3431	0	3066	684	146	73	370	38.6	4.66	84	12.8	1.70				
2228	2	41													1.40				
2229	2	51	10600	6986	0	4200	0	316	0	296	40.0	4.47	89	13.6					
2230	2	46	9200	6980	0	2852	164	0	184	339	41.1	4.94	83	14.2	1.60			174.0	10.1
2231	2	34	6900	3864	0	2622	138	207	0	378	42.7	6.01	85	14.8	2.00	2.8		223.0	
2232	1	36	9700	6238	194	3492	776	0	0	260	61.8	6.40	96	17.3	2.10				
2234	1	48	8200	3690	164	3826	738	82	0	280	46.3	6.04	90	16.7	3.40				
2236	1	40	8400	4536	0	2604	1008	166	0	260	42.7	4.64	92	14.6	.70				
2236	1	44	4900	1764	0	2646	392	0	98	295	42.9	4.97	86	14.6	.70				
2239	2	36	8200	6668	0	1394	410	668	82	346	34.1	3.92	87	12.0	2.00				
2242	1	33	8000	4960	0	2480	320	240	0	266	47.3	6.03	94	16.6	1.60				
2244	2	77	4900	1911	0	2460	490	0	49	280	34.6	3.67	97	11.7	3.10			143.0	9.4
2246	1	33	13400	6666	0	6226	1206	268	134	269	44.6	4.60	97	16.7	4.10				
2247	2	41	9100	4680	0	3003	273	1183	91	270	37.4	3.94	95	12.4	1.20				
2248	2	48	8600	4848	0	2380	426	695	268	286	42.6	6.06	84	14.6				244.0	11.2
2250	1	43	8600	3488	0	3996	610	426	86	230	46.9	6.49	89	16.7	1.10				
2251	2	38	6600	4686	0	1618	330	66	66	406	32.9	4.41	76	10.6	6.30				
2264	2	37	6000	3180	0	2400	360	80	0	37.4	4.64	62	12.7	4.10					
2266	2	33	8600	3740	0	3626	610	170	170	166	43.6	4.64	90	14.3	1.40				
2266	2	38	7800	6382	0	2028	234	166	0	420	36.8	4.39	88	13.2	1.10			380.0	12.2
2267	1	40	7400	3774	0	2738	666	74	74	226	46.3	6.21	87	16.0	.70				
2268	2	33	8100	3607	0	3726	324	162	81	360	40.0	4.66	88	14.7	1.10				
2261	1	66	6800	3422	0	1608	622	348	0	190	60.6	6.49	92	16.0	2.90				
2266	1	32	7100	3906	0	2201	662	142	0	176	46.6	6.63	86	17.0	1.70			106.0	
2269	1	32	7800	4446	0	2652	468	166	78	266	46.0	4.78	96	16.0	2.00			6.9	
2271	1	32	8100	4293	0	2997	466	243	81	360	46.6	6.16	90	16.8	2.00			172.0	10.3
2273	1	33	9700	6236	0	2619	1466	291	97	326	61.6	6.04	86	17.7	1.60				
2274	1	32	7000	2240	0	4130	420	70	70	226	46.6	6.36	86	16.3	1.30				
2276	1	33	10200	6916	0	3670	610	102	102	200	47.0	6.61	91	16.7	1.90			179.0	8.8
2277	2	33													1.70				
808	2	33	8100	2040	0	2660	204	306	0	336	36.0	4.34	81	12.1					
811	2	33	9000	3240	0	6400	90	180	90	276	36.6	3.69	99	14.2	1.80				
816	1	37	6700	2880	0	2337	342	171	0	206	46.3	6.06	92	16.6					
816	2	37	6900	3864	0	2416	662	0	69	230	40.6	4.67	89	13.6					
818	1	36	7300	3266	0	3677	146	292	0	370	39.8	4.36	91	13.6					
822	1	41	8100	3233	0	2267	122	427	61	180	42.6	4.74	90	14.6					
823	1	43	7300	4699	0	1971	219	439	73	220	42.6	4.34	96	13.8					
826	2	46	8900	6963	0	2403	634	0	0	300	41.6	6.07	82	12.9					
826	2	50	6000	2780	0	1400	200	660	0	240	36.9	4.06	89	11.9					
829	2	49	4600	1932	0	2300	138	230	0	360	36.8	3.97	93	12.4	.20				
830	1	46	6400	4416	0	1600	128	266	0	306	39.6	4.12	96	14.1				96.0	12.8
831	1	46	6600	2904	0	2904	330	462	0	340	46.0	4.64	96	16.3					
832	2	49	8600	6696	0	2200	264	440	0	260	39.2	4.66	84	13.0					

5004141

COMPUTER LISTING OF 1987 RAW DATA

PID	SEX	AGE	WBC	PHN	BAND	LYMPH	MONO	EOS	BAZO	PLT	HCT	RBC	MCV	HGB	TSH	PRL	T4	FBS	HBAIC
833	1	54	8000	1780	0	2960	60	100	0	200	44.2	6.23	86	14.6					
834	1	53	8700	3688	0	2546	336	134	0	366	46.0	4.99	90	16.0					
836	2	53	6200	2418	0	3348	248	62	124	220	43.1	4.49	96	16.0			218.0	6.7	
838	1	54	7100	3634	0	2982	71	213	0	233	46.8	4.76	97	16.0			89.0		
839	2	59	9900	2673	99	6336	693	99	0	210	42.2	4.62	93	16.1			114.0		
841	2	54	10900	7987	0	1962	872	327	0	237	36.1	4.06	89	12.6	1.80		109.0		
843	2	56	7200	3024	144	2608	360	864	0	236	36.2	3.93	92	13.0					
844	2	58	6400	2636	0	2636	162	162	0	210	41.2	4.41	93	12.8					
846	1	57	7400	4218	0	2220	740	222	0	196	47.0	5.06	93	14.3					
851	2	77	6200	3906	0	1922	186	310	62	200	33.3	3.36	99	11.9			169.0	8.3	
867	2	58	6600	2662	0	4012	0	136	0	200	42.6	4.69	91	14.1			187.0	10.4	
861	1	54	7700	4620	0	2166	616	164	164	160	44.4	4.64	92	13.9			118.0	7.1	
862	1	54	6200	3666	0	1964	434	124	0	186	42.6	5.04	86	14.8			108.0	7.1	
863	1	76	6800	2664	0	3672	408	136	0	200	42.8	4.24	101	14.3	3.40				
866	2	57	7600	3976	0	3226	226	0	76	246	39.7	4.36	91	13.6					
891	2	38	7400	4218	0	2980	74	146	0	406	36.4	3.90	90	12.1					
896	2	47	7100	3124	0	2696	710	666	0	430	37.2	4.26	87	12.6					
909	2	37	8100	3240	0	3666	406	466	61	300	40.6	4.29	94	13.4					
911	2	34	6600	2610	0	2610	232	174	174	280	43.0	4.76	90	13.3					
912	1	34	7600	3344	0	3266	466	466	76	260	40.2	4.62	87	14.0					
914	2	52	9600	6060	0	2376	0	1046	0	296	36.7	4.16	86	12.7					
917	1	66	11600	7016	0	3660	676	116	116	270	32.7	4.01	82	11.7			162.0	8.0	
920	1	56	6600	4762	66	3606	264	66	0	169	41.4	4.41	94	14.6			139.0		
922	2	62	12100	4719	121	6171	242	647	0	390	36.6	3.94	93	13.2					
926	2	36	6900	4626	0	3293	69	601	69	400	39.3	4.76	63	13.1					
926	2	74	4700	1633	0	2266	0	611	0	216	29.7	2.99	99	10.2					
931	1	33	6100	2696	0	2142	469	163	61	296	46.7	4.62	99	16.3					
932	2	62	8000	3920	0	3120	320	460	160	306	34.1	3.62	97	11.6					
934	2	62	7600	2660	160	3376	460	376	300	396	43.1	6.01	66	14.6					
936	2	54	7600	4366	0	2606	390	234	0	176	36.2	4.61	66	13.0	3.70				
939	1	41	6900	6406	0	1966	366	366	176	260	46.9	6.01	93	16.0					
941	2	66	6900	4276	0	2416	69	0	136	336	36.6	4.14	93	12.6					
942	2	72	4600	2266	0	1966	266	266	0	296	36.0	3.76	93	12.3			10.9	91.0	6.2
944	1	62	6100	3402	0	3402	610	466	0	226	43.6	6.17	64	16.4					
956	2	36	6300	3067	0	2772	63	376	63	220	36.0	3.96	96	12.6					
956	1	56	10600	6670	210	3266	316	946	0	326	36.6	4.04	91	12.4					
960	2	36	11900	7376	0	3669	696	119	119	260	34.3	3.61	90	11.6					
963	1	69	9100	6276	0	3166	91	646	0	240	43.1	4.71	92	14.6					
966	2	43	6900	6340	0	2661	267	712	0	346	36.9	4.14	69	12.6	2.40				9.6
966	1	56	7900	6461	79	1601	316	474	79	600	36.7	3.76	96	12.4					
969	1	69	6600	6696	0	2266	264	362	0	316	39.6	4.11	96	13.6					
970	2	73	7400	4144	0	3034	0	74	146	160	26.6	2.60	96	6.6					
971	1	44	7700	3927	0	3003	164	306	164	346	43.4	4.97	87	14.2					
960	2	34	6700	2337	0	2907	171	226	67	246	41.6	4.64	90	13.9	.90				
981	1	33																	
993	2	40	6200	1736	0	4030	310	62	62	316	40.7	4.64	66	14.2					
996	2	39	6700	4020	0	2346	201	134	0	236	41.0	4.62	69	14.3			218.0	9.2	
1001	2	53	7600	6226	0	2262	234	76	0	206	44.3	6.39	62	15.1					
1007	1	76	6000	3960	0	1740	160	120	0	260	36.6	4.06	90	12.6			13.6	124.0	7.6
1036	1	36	6700	1767	0	3363	613	67	0	320	46.7	6.66	66	16.6					
1600	1	66	10000	6200	0	3700	900	100	100	370	41.7	4.67	69	13.1			120.0	11.6	
1619	1	44	6900	6230	0	2492	176	0	0	326	46.6	4.90	63	16.7					7.1
1620	2	66	6300	6229	0	2739	63	63	63	176	41.9	4.94	66	14.3			267.0	10.3	
1624	1	44	10300	6671	0	4017	206	206	0	226	44.1	4.66	96	16.1					

5004142

COMPUTER LISTING OF 1987 RAW DATA

PID	SEX	AGE	WBC	PMN	BAND	LYMPH	MONO	EOS	BASO	PLT	HCT	RBC	MCV	HGB	TSH	PRL	T4	FBS	HBA1C
1828	1	58	13100	6943	0	4061	524	1310	282	285	41.9	4.85	90	14.3				101.0	8.8
1833	1	34																	
1841	2	59	7900	4187	0	3081	188	318	188	190	38.3	4.28	89	13.3					
1848	1	73	6100	3680	81	2138	183	61	0	130	44.8	4.71	95	18.0			207.0	11.0	
1848	2	45	11200	6048	672	2688	224	448	0	300	34.0	3.73	91	12.2					
1852	1	57	6100	2989	0	2684	122	183	122	220	41.0	4.66	90	14.0					
1853	1	38	8000	3680	0	2880	720	640	80	280	42.7	4.38	97	14.4					
1858	2	44	8400	4788	84	2940	282	168	168	280	43.9	5.58	79	14.9				10.0	
1866	2	42	6700	1878	0	4221	836	0	67	238	41.0	4.19	98	13.8	4.40				
1867	1	39	8400	3948	0	3580	282	840	0	228	38.7	3.99	92	13.2			95.0		
1869	2	34	9800	4018	198	4704	784	98	0	278	40.8	4.98	81	13.4					
1880	2	63	7900	3713	0	3397	863	79	0	188	43.9	4.88	98	14.7					
1881	2	69	8000	4980	0	2320	400	320	0	330	38.4	3.77	97	13.0					
1884	2	38	10600	4028	0	6612	530	318	212	330	39.7	4.48	89	12.9					
1886	1	42	8400	3948	0	3612	84	672	84	338	46.2	4.67	99	18.8					
1887	2	33	6200	2768	0	2028	104	208	104	288	38.3	4.04	87	11.8					
1877	2	38																	
1878	2	51	7400	2738	0	3182	1184	148	148	330	44.4	5.18	88	18.4			217.0	12.8	